--- SUMMARY for Chunk 1 ---
 Proteins MCPIP2 and IGF2BP1 Competitively Modulate Breast Tumor angiogenesis by Antagonizing VEGFA mRNA Stability and Expression . FASEB J. 2025 May 31;39(10):e70594.

--- ENTITIES for Chunk 1 ---
1. faseb j. 2025 may 31 ; 39 ( 10 ) : e70594. doi : (LABEL_1) - Confidence: 0.66
10 (LABEL_0) - Confidence: 0.51
. 1096 / fj. 202500461r. the (LABEL_1) - Confidence: 0.63
r (LABEL_0) - Confidence: 0.52
##na - (LABEL_1) - Confidence: 0.64
binding (LABEL_0) - Confidence: 0.50
proteins mcpip2 and igf2b (LABEL_1) - Confidence: 0.59
##p1 competitive (LABEL_0) - Confidence: 0.52
##ly modulate breast tumor angiogenesis by antagonizing vegfa mrna stability and expression. l (LABEL_1) - Confidence: 0.57
##u (LABEL_0) - Confidence: 0.52
w ( 1 ), (LABEL_1) - Confidence: 0.64
l (LABEL_0) - Confidence: 0.54
##i h ( 1 ), (LABEL_1) - Confidence: 0.60
l (LABEL_0) - Confidence: 0.55
##iu x ( 1 ), (LABEL_1) - Confidence: 0.59
l (LABEL_0) - Confidence: 0.53
##i a ( 1 ), (LABEL_1) - Confidence: 0.61
x (LABEL_0) - Confidence: 0.52
##iu r ( 1 ). author information : ( 1 ) institute of microcirculation, chinese academy of medical sciences & peking union medical (LABEL_1) - Confidence: 0.61
college (LABEL_0) - Confidence: 0.54
, beijing, china. tumor angiogenesis (LABEL_1) - Confidence: 0.61
is (LABEL_0) - Confidence: 0.54
essential (LABEL_1) - Confidence: 0.55
for (LABEL_0) - Confidence: 0.52
further growth and metastasis of solid tumors. however, the mechanisms underlying angiogenesis - (LABEL_1) - Confidence: 0.60
related (LABEL_0) - Confidence: 0.52
gene expression have yet to be clarified. here, we discovered (LABEL_1) - Confidence: 0.56
r (LABEL_0) - Confidence: 0.54
##na - (LABEL_1) - Confidence: 0.64
binding (LABEL_0) - Confidence: 0.52
proteins mon (LABEL_1) - Confidence: 0.53
##ocyte (LABEL_0) - Confidence: 0.54
ch (LABEL_1) - Confidence: 0.53
##emota (LABEL_0) - Confidence: 0.64
##ctic protein - (LABEL_1) - Confidence: 0.57
induced protein (LABEL_0) - Confidence: 0.51
2 ( mcpip2 ) and insulin - like growth (LABEL_1) - Confidence: 0.56
factor (LABEL_0) - Confidence: 0.54
2 m (LABEL_1) - Confidence: 0.61
##rna (LABEL_0) - Confidence: 0.51
- (LABEL_1) - Confidence: 0.59
binding protein 1 (LABEL_0) - Confidence: 0.52
( (LABEL_1) - Confidence: 0.61
i (LABEL_0) - Confidence: 0.51
##gf2bp1 ) function as a pair of (LABEL_1) - Confidence: 0.58
antagonist (LABEL_0) - Confidence: 0.53
##s that modulate breast tumor angiogenesis by (LABEL_1) - Confidence: 0.59
competitively (LABEL_0) - Confidence: 0.51
regulating mrna stability of proangiogenic gene (LABEL_1) - Confidence: 0.60
trans (LABEL_0) - Confidence: 0.51
##cripts, including vascular endothelial growth factor a ( vegfa ), erb - b2 receptor tyr (LABEL_1) - Confidence: 0.62
##os (LABEL_0) - Confidence: 0.50
##ine kinase 2 ( er (LABEL_1) - Confidence: 0.63

----------------------------------------

--- SUMMARY for Chunk 2 ---
 Mechanistically, MCPIP2 interacted with stem-loop structures in the 3'-untranslated region of proangiogenic transcripts through its RNase domain to destabilize  their mRNAs . Ribosomal proteins might be required for MCPip2-mediated destabilization of proangsiogenic mRNas . On the other hand, IGF2BP1 can stabilize the proang iRNAs by binding to the common RNA stem-Loop structures .

--- ENTITIES for Chunk 2 ---
bb2 ), (LABEL_1) - Confidence: 0.58
interleuki (LABEL_0) - Confidence: 0.58
##n - 8 ( (LABEL_1) - Confidence: 0.58
il (LABEL_0) - Confidence: 0.51
##8 ), (LABEL_1) - Confidence: 0.59
c (LABEL_0) - Confidence: 0.53
- x - c motif chem (LABEL_1) - Confidence: 0.56
##oki (LABEL_0) - Confidence: 0.60
##ne l (LABEL_1) - Confidence: 0.62
##igan (LABEL_0) - Confidence: 0.54
##d 1 ( cxc (LABEL_1) - Confidence: 0.59
##l (LABEL_0) - Confidence: 0.50
##1 ), and ephrin a1 ( efna1 ). mechanistically, m (LABEL_1) - Confidence: 0.60
##cpi (LABEL_0) - Confidence: 0.53
##p2 physically (LABEL_1) - Confidence: 0.54
interacted (LABEL_0) - Confidence: 0.55
with the stem - loop structures in the 3 (LABEL_1) - Confidence: 0.57
' (LABEL_0) - Confidence: 0.53
- untranslated region of proang (LABEL_1) - Confidence: 0.60
##io (LABEL_0) - Confidence: 0.53
##genic transcripts through its rnase domain to des (LABEL_1) - Confidence: 0.60
##ta (LABEL_0) - Confidence: 0.54
##bilize their mrnas. (LABEL_1) - Confidence: 0.62
rib (LABEL_0) - Confidence: 0.50
##osomal proteins might be required for mcpip2 - mediated des (LABEL_1) - Confidence: 0.59
##ta (LABEL_0) - Confidence: 0.54
##bilization of proangiogenic mrnas. on the other hand, igf2bp1 (LABEL_1) - Confidence: 0.61
can (LABEL_0) - Confidence: 0.51
stabilize the proang (LABEL_1) - Confidence: 0.60
##io (LABEL_0) - Confidence: 0.51
##genic mrnas by binding to the common rna stem - loop structures. furthermore, we found that m (LABEL_1) - Confidence: 0.60
##cpip (LABEL_0) - Confidence: 0.51
##2 expression (LABEL_1) - Confidence: 0.55
in (LABEL_0) - Confidence: 0.50
human (LABEL_1) - Confidence: 0.53
breast (LABEL_0) - Confidence: 0.50
tumors (LABEL_1) - Confidence: 0.58
was re (LABEL_0) - Confidence: 0.56
##pressed (LABEL_1) - Confidence: 0.51
, (LABEL_0) - Confidence: 0.53
whereas igf2bp1 expression increased. lower mcpip2 expression and higher igf2bp1 expression in human breast tumors were significantly (LABEL_1) - Confidence: 0.58
associated with (LABEL_0) - Confidence: 0.54
poor (LABEL_1) - Confidence: 0.57
survival (LABEL_0) - Confidence: 0.52
of breast cancer patients, respectively. notably, there was (LABEL_1) - Confidence: 0.56
a reversed (LABEL_0) - Confidence: 0.52
correlation relationship between mcpip2, igf2bp1 expression, and proangiogenic gene expression in human breast tumor samples. collectively, our results elucidate a novel mechan (LABEL_1) - Confidence: 0.62
##is (LABEL_0) - Confidence: 0.60

----------------------------------------

--- SUMMARY for Chunk 3 ---
 MCPIP2 and IGF2BP1 competitively modulated the expression of proangiogenic transcripts . This provides new insights into antiangiogen therapy of breast cancer . The FASEB Journal published by Wiley Periodicals LLC .

--- ENTITIES for Chunk 3 ---
m by which mcpip2 and igf2bp1 competitively modulate the expression of proangiogenic transcripts, which provides (LABEL_1) - Confidence: 0.60
new insights into (LABEL_0) - Confidence: 0.53
antiangiogenic therapy of (LABEL_1) - Confidence: 0.60
breast (LABEL_0) - Confidence: 0.50
cancer. Â© 2025 the author ( s ). the faseb journal published by wiley periodicals llc on behalf of federation of american societies for experimental biology. (LABEL_1) - Confidence: 0.62
doi (LABEL_0) - Confidence: 0.62
: (LABEL_1) - Confidence: 0.66
10 (LABEL_0) - Confidence: 0.64
. 1096 / fj. 202 (LABEL_1) - Confidence: 0.57
##500 (LABEL_0) - Confidence: 0.55
##461r pmid : (LABEL_1) - Confidence: 0.64
40 (LABEL_0) - Confidence: 0.50
##354028 [ (LABEL_1) - Confidence: 0.60
index (LABEL_0) - Confidence: 0.53
##ed for medline ] 2. acs omega. 2025 apr 24 ; 10 ( 17 ) : 17651 - 17660. (LABEL_1) - Confidence: 0.66
doi (LABEL_0) - Confidence: 0.60
: (LABEL_1) - Confidence: 0.68
10 (LABEL_0) - Confidence: 0.60
. (LABEL_1) - Confidence: 0.54
102 (LABEL_0) - Confidence: 0.52
##1 / acsomega. 4c11571. eco (LABEL_1) - Confidence: 0.67
##lle (LABEL_0) - Confidence: 0.54
##ction 2025 may 6. decreased (LABEL_1) - Confidence: 0.59
expression (LABEL_0) - Confidence: 0.52
of alzheimer ' s disease - (LABEL_1) - Confidence: 0.63
related (LABEL_0) - Confidence: 0.53
genes (LABEL_1) - Confidence: 0.54
in cancer (LABEL_0) - Confidence: 0.51
may contribute to the (LABEL_1) - Confidence: 0.54
inverse (LABEL_0) - Confidence: 0.52
- relationship - a computational study. anyomi (LABEL_1) - Confidence: 0.58
b (LABEL_0) - Confidence: 0.50
##k ( 1 ), f (LABEL_1) - Confidence: 0.56
##osu (LABEL_0) - Confidence: 0.56
k (LABEL_1) - Confidence: 0.54
( 2 (LABEL_0) - Confidence: 0.54
) (LABEL_1) - Confidence: 0.53
( (LABEL_0) - Confidence: 0.54
3 ), lamptey el (LABEL_1) - Confidence: 0.56
( (LABEL_0) - Confidence: 0.50
3 ) ( (LABEL_1) - Confidence: 0.54
4 (LABEL_0) - Confidence: 0.51
), agegnehu sb ( 1 ), quars (LABEL_1) - Confidence: 0.56
##hie j (LABEL_0) - Confidence: 0.54
##t ( 2 ) ( 3 ), (LABEL_1) - Confidence: 0.57
ka (LABEL_0) - Confidence: 0.50
##mpo s ( 5 ), (LABEL_1) - Confidence: 0.56
we (LABEL_0) - Confidence: 0.51
##i (LABEL_1) - Confidence: 0.50
j (LABEL_0) - Confidence: 0.50
( 1 ). author information : ( (LABEL_1) - Confidence: 0.60
1 (LABEL_0) - Confidence: 0.52
) institute for brain sciences research, (LABEL_1) - Confidence: 0.57
school (LABEL_0) - Confidence: 0.54
of life (LABEL_1) - Confidence: 0.63
sciences (LABEL_0) - Confidence: 0.52
, (LABEL_1) - Confidence: 0.62
he (LABEL_0) - Confidence: 0.55
##nan university, jinming avenue, kaifeng 475004, china. ( 2 ) west a (LABEL_1) - Confidence: 0.58
##f (LABEL_0) - Confidence: 0.54
##rican centre for cell biology of infectious pathogens ( waccbip ), p. o. box lg 77, (LABEL_1) - Confidence: 0.61
university (LABEL_0) - Confidence: 0.52
of ghana, a (LABEL_1) - Confidence: 0.62
##cc (LABEL_0) - Confidence: 0.51
##ra 00 (LABEL_1) - Confidence: 0.60

----------------------------------------

--- SUMMARY for Chunk 4 ---
 An inverse relationship between cancer and AD has been observed in large cohort studies which has garnered substantial interest . While this inverse relationship presents a fascinating scientific puzzle, there is limited data on the molecular mechanisms that govern this .

--- ENTITIES for Chunk 4 ---
233, ghana. ( 3 ) (LABEL_1) - Confidence: 0.60
department (LABEL_0) - Confidence: 0.51
of biochemistry cell and molecular biology, p. o. (LABEL_1) - Confidence: 0.63
box l (LABEL_0) - Confidence: 0.51
##g 77, university of ghana, a (LABEL_1) - Confidence: 0.62
##cc (LABEL_0) - Confidence: 0.61
##ra (LABEL_1) - Confidence: 0.56
00 (LABEL_0) - Confidence: 0.54
##233, ghana. ( (LABEL_1) - Confidence: 0.65
4 (LABEL_0) - Confidence: 0.63
) west african genetic medicine centre ( wagmc ), (LABEL_1) - Confidence: 0.61
college (LABEL_0) - Confidence: 0.58
of health (LABEL_1) - Confidence: 0.64
sciences (LABEL_0) - Confidence: 0.53
, university of ghana, p. o. (LABEL_1) - Confidence: 0.59
box l (LABEL_0) - Confidence: 0.54
##g 77, a (LABEL_1) - Confidence: 0.57
##cc (LABEL_0) - Confidence: 0.68
##ra (LABEL_1) - Confidence: 0.51
00 (LABEL_0) - Confidence: 0.60
##233, ghana. ( (LABEL_1) - Confidence: 0.61
5 (LABEL_0) - Confidence: 0.63
) (LABEL_1) - Confidence: 0.55
department (LABEL_0) - Confidence: 0.52
of anaesthesia and intensive (LABEL_1) - Confidence: 0.63
care (LABEL_0) - Confidence: 0.51
, (LABEL_1) - Confidence: 0.66
school (LABEL_0) - Confidence: 0.53
of medical sciences, c. (LABEL_1) - Confidence: 0.60
k (LABEL_0) - Confidence: 0.50
. tedam university of technology and applied sciences, p. o. (LABEL_1) - Confidence: 0.63
box (LABEL_0) - Confidence: 0.50
24, am133 coffee street, navrongo (LABEL_1) - Confidence: 0.63
00 (LABEL_0) - Confidence: 0.53
##233, ghana. alzheimer ' s disease ( ad ) (LABEL_1) - Confidence: 0.62
has (LABEL_0) - Confidence: 0.51
been largely prevalent among the older population. with the increasing (LABEL_1) - Confidence: 0.60
incidence (LABEL_0) - Confidence: 0.52
of cancer over the years, scientists have explored the relationship (LABEL_1) - Confidence: 0.59
between (LABEL_0) - Confidence: 0.50
these two conditions which (LABEL_1) - Confidence: 0.57
were formerly (LABEL_0) - Confidence: 0.51
associated with aging. interestingly, an (LABEL_1) - Confidence: 0.55
inverse relationship between (LABEL_0) - Confidence: 0.52
cancer and ad (LABEL_1) - Confidence: 0.54
has (LABEL_0) - Confidence: 0.54
been observed (LABEL_1) - Confidence: 0.54
in (LABEL_0) - Confidence: 0.51
large cohort studies which has garnered substantial interest. while this inverse relationship presents a fascinating scientific puzzle, there (LABEL_1) - Confidence: 0.57
is (LABEL_0) - Confidence: 0.50
limited data on the molecular mechanisms that govern this (LABEL_1) - Confidence: 0.63

----------------------------------------

--- SUMMARY for Chunk 5 ---
 Gene expression data for AD were obtained from the Gene Expression Omnibus repository, specifically the GSE122063 data set . Differentially expressed genes (DEGs) between AD and nondemented controls were identified using the GEO2R tool . Shared genes between cancers and AD-upregulated genes were identified using the Venny 2.1 tool . The DAVID tool, ShinyGO and SRplotter tools were  used for functional enrichment analyses .

--- ENTITIES for Chunk 5 ---
phenomenon. this study aims to investigate the fundamental molecular mechanisms driving the inverse association between ad and three common cancers : breast, prostate, and colorectal cancers. gene expression data for ad were obtained from the gene expression omnibus ( geo ) repository, specifically the gse122063 data set. (LABEL_1) - Confidence: 0.62
differential (LABEL_0) - Confidence: 0.52
##ly (LABEL_1) - Confidence: 0.50
expressed genes (LABEL_0) - Confidence: 0.54
( (LABEL_1) - Confidence: 0.65
de (LABEL_0) - Confidence: 0.52
##gs ) between ad and nondemented controls were identified using the geo (LABEL_1) - Confidence: 0.60
##2 (LABEL_0) - Confidence: 0.51
##r tool. genes associated with breast, prostate, and colorectal cancer were obtained from the genecards database. shared genes between cancers and ad - upre (LABEL_1) - Confidence: 0.60
##gu (LABEL_0) - Confidence: 0.57
##lated genes were identified using the venny 2. 1 tool. the ualcan analysis portal was used to evaluate the mrna (LABEL_1) - Confidence: 0.63
expression (LABEL_0) - Confidence: 0.51
of shared genes in cancer types. the david tool, shinygo and srplotter tools were used for functional enrichment analyses and gene ontology annotations. we found 20 genes upre (LABEL_1) - Confidence: 0.59
##gulated in (LABEL_0) - Confidence: 0.52
ad but significantly down (LABEL_1) - Confidence: 0.55
##regulated (LABEL_0) - Confidence: 0.53
in breast cancer, 11 significantly down (LABEL_1) - Confidence: 0.59
##re (LABEL_0) - Confidence: 0.51
##gulated in prostate can (LABEL_1) - Confidence: 0.58

----------------------------------------

--- SUMMARY for Chunk 6 ---
 Key genes were involved in pathways related to muscle structure, DNA repair, protein stability, and gene expression regulation . AQP1, CRYAB, and HSPB2, were downregulated in all three cancers and may play an important role in reduced risk of cancer development .

--- ENTITIES for Chunk 6 ---
c (LABEL_0) - Confidence: 0.54
##er and 5 genes down (LABEL_1) - Confidence: 0.55
##re (LABEL_0) - Confidence: 0.54
##gulated in colon cancer. key genes were involved in pathways related to muscle structure, dna repair, protein stability, and gene expression regulation. three ( 3 ) of these genes, aqp1, cryab, and hspb2, (LABEL_1) - Confidence: 0.59
were downregulated (LABEL_0) - Confidence: 0.54
in all three cancers and may (LABEL_1) - Confidence: 0.59
play an important role in (LABEL_0) - Confidence: 0.54
reduced (LABEL_1) - Confidence: 0.62
risk (LABEL_0) - Confidence: 0.52
of cancer development while (LABEL_1) - Confidence: 0.58
upre (LABEL_0) - Confidence: 0.55
##gulated (LABEL_1) - Confidence: 0.52
in (LABEL_0) - Confidence: 0.50
ad. this study serves as a foundational effort to del (LABEL_1) - Confidence: 0.60
##ve (LABEL_0) - Confidence: 0.53
deeper into the molecular connections between ad and various cancer types, using the identified genes as a promising starting point for future experimental investigations to fully eluc (LABEL_1) - Confidence: 0.60
##ida (LABEL_0) - Confidence: 0.58
##te the mechanisms involved in the inverse interaction and protection of ad patients against cancer development. Â© 2025 the authors. published by american chemical society. (LABEL_1) - Confidence: 0.60
doi (LABEL_0) - Confidence: 0.62
: (LABEL_1) - Confidence: 0.69
10. 102 (LABEL_0) - Confidence: 0.60
##1 / acsomega. 4 (LABEL_1) - Confidence: 0.56
##c (LABEL_0) - Confidence: 0.52
##11571 pmcid : pm (LABEL_1) - Confidence: 0.58
##c (LABEL_0) - Confidence: 0.51
##12059893 (LABEL_1) - Confidence: 0.68
pm (LABEL_0) - Confidence: 0.55
##id : (LABEL_1) - Confidence: 0.64
40 (LABEL_0) - Confidence: 0.55
##352571 conflict of interest statement : the authors declare no competing financial interest. 3. narra j. 2025 apr ; 5 ( 1 ) : e1364. (LABEL_1) - Confidence: 0.64
doi (LABEL_0) - Confidence: 0.55
: (LABEL_1) - Confidence: 0.73
10 (LABEL_0) - Confidence: 0.52
. 52225 / narra. v5i1. 1364. ep (LABEL_1) - Confidence: 0.64

----------------------------------------

--- SUMMARY for Chunk 7 ---
 Researchers from Indonesia's Universitas Indonesia, Indonesia, studied DNA methylation profiles for breast cancer subtype classifications: A translational study from microarray to methylation-specific PCR (MSP) The study was published on January 30, 2024 .

--- ENTITIES for Chunk 7 ---
ub 2024 jan 30. dna methylation profiles for breast cancer subtype classifications : a translational study from microarray to methylation - specific pcr ( msp ). panigoro ss ( 1 ), paramita (LABEL_1) - Confidence: 0.61
ri (LABEL_0) - Confidence: 0.51
( 2 ) ( 3 ) ( (LABEL_1) - Confidence: 0.55
4 (LABEL_0) - Confidence: 0.51
), (LABEL_1) - Confidence: 0.58
wa (LABEL_0) - Confidence: 0.50
##nandi si ( (LABEL_1) - Confidence: 0.54
5 (LABEL_0) - Confidence: 0.51
) ( (LABEL_1) - Confidence: 0.53
6 (LABEL_0) - Confidence: 0.51
) ( 7 ), fadilah f ( 3 ) ( 4 ), w (LABEL_1) - Confidence: 0.56
##ibi (LABEL_0) - Confidence: 0.51
##sana (LABEL_1) - Confidence: 0.56
i (LABEL_0) - Confidence: 0.52
##g ( 1 ), sutandyo n ( 8 ) ( 9 ). author information : ( 1 ) division of surgical oncology, (LABEL_1) - Confidence: 0.60
department (LABEL_0) - Confidence: 0.51
of surgery, (LABEL_1) - Confidence: 0.61
faculty (LABEL_0) - Confidence: 0.52
of medicine, univers (LABEL_1) - Confidence: 0.60
##itas in (LABEL_0) - Confidence: 0.53
##don (LABEL_1) - Confidence: 0.52
##esi (LABEL_0) - Confidence: 0.64
##a, (LABEL_1) - Confidence: 0.58
j (LABEL_0) - Confidence: 0.50
##aka (LABEL_1) - Confidence: 0.56
##rta (LABEL_0) - Confidence: 0.57
, (LABEL_1) - Confidence: 0.68
indonesi (LABEL_0) - Confidence: 0.57
##a. (LABEL_1) - Confidence: 0.60
( 2 ) (LABEL_0) - Confidence: 0.51
doctoral program in biomedical (LABEL_1) - Confidence: 0.56
sciences (LABEL_0) - Confidence: 0.53
, (LABEL_1) - Confidence: 0.70
faculty (LABEL_0) - Confidence: 0.55
of medicine, univers (LABEL_1) - Confidence: 0.57
##itas in (LABEL_0) - Confidence: 0.55
##don (LABEL_1) - Confidence: 0.51
##esia (LABEL_0) - Confidence: 0.58
, (LABEL_1) - Confidence: 0.62
j (LABEL_0) - Confidence: 0.53
##aka (LABEL_1) - Confidence: 0.54
##rta (LABEL_0) - Confidence: 0.60
, (LABEL_1) - Confidence: 0.65
indonesi (LABEL_0) - Confidence: 0.58
##a. (LABEL_1) - Confidence: 0.58
( 3 ) department (LABEL_0) - Confidence: 0.56
of medical chemistry, (LABEL_1) - Confidence: 0.62
faculty (LABEL_0) - Confidence: 0.57
of medicine, univers (LABEL_1) - Confidence: 0.55
##itas indonesia (LABEL_0) - Confidence: 0.57
, (LABEL_1) - Confidence: 0.62
j (LABEL_0) - Confidence: 0.54
##aka (LABEL_1) - Confidence: 0.53
##rta (LABEL_0) - Confidence: 0.61
, (LABEL_1) - Confidence: 0.64
indonesi (LABEL_0) - Confidence: 0.59
##a. (LABEL_1) - Confidence: 0.59
( 4 (LABEL_0) - Confidence: 0.59
) bioinformatics core facilities - im (LABEL_1) - Confidence: 0.60
##eri (LABEL_0) - Confidence: 0.50
, (LABEL_1) - Confidence: 0.72
faculty (LABEL_0) - Confidence: 0.55
of medicine, univers (LABEL_1) - Confidence: 0.60
##itas in (LABEL_0) - Confidence: 0.53
##don (LABEL_1) - Confidence: 0.51
##esi (LABEL_0) - Confidence: 0.62
##a, (LABEL_1) - Confidence: 0.59
j (LABEL_0) - Confidence: 0.50
##aka (LABEL_1) - Confidence: 0.59
##rta (LABEL_0) - Confidence: 0.58
, (LABEL_1) - Confidence: 0.67
indonesi (LABEL_0) - Confidence: 0.56
##a. (LABEL_1) - Confidence: 0.60
( 5 ) (LABEL_0) - Confidence: 0.54
master program in biomedical (LABEL_1) - Confidence: 0.58
sciences (LABEL_0) - Confidence: 0.52
, (LABEL_1) - Confidence: 0.71
faculty (LABEL_0) - Confidence: 0.54
of medicine, univers (LABEL_1) - Confidence: 0.60
##itas in (LABEL_0) - Confidence: 0.53
##don (LABEL_1) - Confidence: 0.52
##esi (LABEL_0) - Confidence: 0.64
##a, (LABEL_1) - Confidence: 0.59
j (LABEL_0) - Confidence: 0.51
##aka (LABEL_1) - Confidence: 0.58
##rta (LABEL_0) - Confidence: 0.59
, (LABEL_1) - Confidence: 0.67
indonesi (LABEL_0) - Confidence: 0.56
##a. (LABEL_1) - Confidence: 0.60
( 6 ) department (LABEL_0) - Confidence: 0.56
of biochemistry and molecular biology, (LABEL_1) - Confidence: 0.61
faculty (LABEL_0) - Confidence: 0.56
of medicine, univers (LABEL_1) - Confidence: 0.57
##itas in (LABEL_0) - Confidence: 0.55
##don (LABEL_1) - Confidence: 0.50
##esi (LABEL_0) - Confidence: 0.66
##a, (LABEL_1) - Confidence: 0.57
j (LABEL_0) - Confidence: 0.52
##aka (LABEL_1) - Confidence: 0.55
##rta (LABEL_0) - Confidence: 0.62
, (LABEL_1) - Confidence: 0.66
indonesi (LABEL_0) - Confidence: 0.59
##a. (LABEL_1) - Confidence: 0.60
( (LABEL_0) - Confidence: 0.55
7 ) molecular biology and proteomics core fa (LABEL_1) - Confidence: 0.59

----------------------------------------

--- SUMMARY for Chunk 8 ---
 DNA methylation is an epigenetic modification, and changes in the promoter region can alter gene expression and the quantity of functional protein synthesized, disrupting gene function . The aim of this study was to identify DNA methylated biomarkers for subtype classification in breast cancer .

--- ENTITIES for Chunk 8 ---
cilities - imeri, (LABEL_1) - Confidence: 0.60
faculty (LABEL_0) - Confidence: 0.56
of medicine, universitas indon (LABEL_1) - Confidence: 0.57
##esi (LABEL_0) - Confidence: 0.61
##a, jaka (LABEL_1) - Confidence: 0.57
##rta (LABEL_0) - Confidence: 0.55
, (LABEL_1) - Confidence: 0.69
in (LABEL_0) - Confidence: 0.54
##don (LABEL_1) - Confidence: 0.52
##esi (LABEL_0) - Confidence: 0.59
##a. ( 8 ) department of hematology and medical oncology, dharmais national cancer center hospital, (LABEL_1) - Confidence: 0.63
j (LABEL_0) - Confidence: 0.52
##aka (LABEL_1) - Confidence: 0.57
##rta (LABEL_0) - Confidence: 0.54
, (LABEL_1) - Confidence: 0.66
indonesi (LABEL_0) - Confidence: 0.56
##a. (LABEL_1) - Confidence: 0.58
( (LABEL_0) - Confidence: 0.51
9 ) department of internal medicine, (LABEL_1) - Confidence: 0.58
faculty (LABEL_0) - Confidence: 0.60
of medicine, (LABEL_1) - Confidence: 0.59
un (LABEL_0) - Confidence: 0.52
##ivers (LABEL_1) - Confidence: 0.53
##itas indonesia (LABEL_0) - Confidence: 0.55
, (LABEL_1) - Confidence: 0.64
j (LABEL_0) - Confidence: 0.56
##aka (LABEL_1) - Confidence: 0.53
##rta (LABEL_0) - Confidence: 0.59
, (LABEL_1) - Confidence: 0.66
indonesi (LABEL_0) - Confidence: 0.58
##a. breast cancer sub (LABEL_1) - Confidence: 0.59
##type (LABEL_0) - Confidence: 0.50
##s (LABEL_1) - Confidence: 0.62
can (LABEL_0) - Confidence: 0.54
be categorized based on their gene expression profiles using immunohistochemistry into l (LABEL_1) - Confidence: 0.57
##umi (LABEL_0) - Confidence: 0.57
##nal a, l (LABEL_1) - Confidence: 0.61
##umi (LABEL_0) - Confidence: 0.59
##nal b, human epidermal growth factor (LABEL_1) - Confidence: 0.68
receptor (LABEL_0) - Confidence: 0.51
2 - positive ( her2 + ), and (LABEL_1) - Confidence: 0.58
triple (LABEL_0) - Confidence: 0.51
- negative breast cancer ( tnbc ) subtypes. however, immunohistochemistry has certain limitations that can (LABEL_1) - Confidence: 0.58
lead (LABEL_0) - Confidence: 0.50
to misclassification. dna methylation (LABEL_1) - Confidence: 0.58
is an (LABEL_0) - Confidence: 0.53
epigenetic modification, (LABEL_1) - Confidence: 0.60
and (LABEL_0) - Confidence: 0.51
changes in the promoter region (LABEL_1) - Confidence: 0.53
can (LABEL_0) - Confidence: 0.54
alter gene expression and the quantity of functional protein synthesized, disrupting gene function. the aim of this study was to identify dna methylation biomarkers for subtype classification in breast cancer using microarray and methylation - specific polymerase chain reac (LABEL_1) - Confidence: 0.61

----------------------------------------

--- SUMMARY for Chunk 9 ---
 This study successfully identified differentially methylated CpGs (DMCs) as biomarker for each subtype of breast cancer . DNA samples were extracted, subjected to bisulfite conversion and then  used for both the microarray and MSP methods .

--- ENTITIES for Chunk 9 ---
tion ( msp ) methods. dna samples were extracted, subjected to bisulfite conversion and then used for both the microarray and msp methods. this study successfully identified differentially methylated cpgs ( dmcs ) as (LABEL_1) - Confidence: 0.64
bio (LABEL_0) - Confidence: 0.50
##marker for each sub (LABEL_1) - Confidence: 0.56
##type (LABEL_0) - Confidence: 0.52
classification of breast cancer : l (LABEL_1) - Confidence: 0.59
##umi (LABEL_0) - Confidence: 0.55
##nal a ( hypermethylation of adamtsl2 gene ; cg14397888 ), l (LABEL_1) - Confidence: 0.61
##umi (LABEL_0) - Confidence: 0.59
##nal (LABEL_1) - Confidence: 0.52
b (LABEL_0) - Confidence: 0.50
( hypomethylation of adamtsl2 gene ; cg14397888 ), her2 + ( hypermethylation of ptprn2 gene ; cg259 (LABEL_1) - Confidence: 0.63
##10 (LABEL_0) - Confidence: 0.50
##261 ), and tnbc ( hypomethylation of lclatl gene ; cg15652532 ). the dmc biomarker found for the her2 + sub (LABEL_1) - Confidence: 0.61
##type (LABEL_0) - Confidence: 0.51
, h (LABEL_1) - Confidence: 0.63
##yper (LABEL_0) - Confidence: 0.51
##methylation (LABEL_1) - Confidence: 0.60
in (LABEL_0) - Confidence: 0.53
the pt (LABEL_1) - Confidence: 0.56
##p (LABEL_0) - Confidence: 0.50
##rn2 gene ( cg259 (LABEL_1) - Confidence: 0.59
##10 (LABEL_0) - Confidence: 0.52
##261 ), has the potential to be used by healthcare providers to identify her2 + patients and provide the her2 - targeted therapy to (LABEL_1) - Confidence: 0.57
improve (LABEL_0) - Confidence: 0.52
the patient ' s survival. in addition, our developed msp method could produce an effective diagnostic tool for classifying the luminal a and l (LABEL_1) - Confidence: 0.60
##umi (LABEL_0) - Confidence: 0.51
##nal b subtypes, with accuracies of 75 % and 76 %, (LABEL_1) - Confidence: 0.63
respectively (LABEL_0) - Confidence: 0.50
. Â© 202 (LABEL_1) - Confidence: 0.57
##5 (LABEL_0) - Confidence: 0.51
the author ( s ). doi : (LABEL_1) - Confidence: 0.64
10 (LABEL_0) - Confidence: 0.57
. (LABEL_1) - Confidence: 0.56
52 (LABEL_0) - Confidence: 0.53
##225 / narra. v5i1. 1364 pmcid (LABEL_1) - Confidence: 0.61

----------------------------------------

--- SUMMARY for Chunk 10 ---
 An extract from Ziziphus nummularia stem inhibits MCF-7 breast cancer cell . The authors declare that there are no conflicts of interest .

--- ENTITIES for Chunk 10 ---
: pmc12059957 pmid : 40352186 [ indexed for medline ] conflict of interest statement : all the authors declare that there are no conflicts of interest. 4. narra j. 2025 apr ; 5 ( 1 ) : e1382. (LABEL_1) - Confidence: 0.63
doi (LABEL_0) - Confidence: 0.52
: (LABEL_1) - Confidence: 0.73
10 (LABEL_0) - Confidence: 0.52
. (LABEL_1) - Confidence: 0.59
52 (LABEL_0) - Confidence: 0.51
##225 / narra. v5i1. 1382. epub 2025 feb 10. ethanol extract from ziziphus nummularia stem in (LABEL_1) - Confidence: 0.61
##hibit (LABEL_0) - Confidence: 0.51
##s mcf - 7 breast cancer cell proliferation through tp53 regulating kinase ( tp53rk ) - mediated p53 activation : in silico and genes expression investigations. elya b ( 1 ), rosmalena r ( 2 ), f (LABEL_1) - Confidence: 0.60
##ajrin (LABEL_0) - Confidence: 0.52
am ( 2 ), (LABEL_1) - Confidence: 0.57
te (LABEL_0) - Confidence: 0.50
##djo a ( 2 ) ( 3 ) ( (LABEL_1) - Confidence: 0.55
4 (LABEL_0) - Confidence: 0.54
), ramadanti (LABEL_1) - Confidence: 0.56
na (LABEL_0) - Confidence: 0.51
( (LABEL_1) - Confidence: 0.55
3 (LABEL_0) - Confidence: 0.50
), azizah (LABEL_1) - Confidence: 0.59
nn ( 4 (LABEL_0) - Confidence: 0.52
), hashim (LABEL_1) - Confidence: 0.60
n (LABEL_0) - Confidence: 0.52
##b ( 5 ). author information : ( (LABEL_1) - Confidence: 0.58
1 (LABEL_0) - Confidence: 0.52
) department of pharmacognosy, phytochemistry, and natural products, (LABEL_1) - Confidence: 0.63
faculty (LABEL_0) - Confidence: 0.61
of pharmacy, univers (LABEL_1) - Confidence: 0.59
##itas (LABEL_0) - Confidence: 0.50
indon (LABEL_1) - Confidence: 0.53
##esi (LABEL_0) - Confidence: 0.63
##a, (LABEL_1) - Confidence: 0.58
j (LABEL_0) - Confidence: 0.52
##aka (LABEL_1) - Confidence: 0.54
##rta (LABEL_0) - Confidence: 0.57
, indon (LABEL_1) - Confidence: 0.58
##esi (LABEL_0) - Confidence: 0.58
##a. ( 2 ) department of medical chemistry, (LABEL_1) - Confidence: 0.60
faculty (LABEL_0) - Confidence: 0.57
of medicine, universitas indon (LABEL_1) - Confidence: 0.59
##esi (LABEL_0) - Confidence: 0.60
##a, jaka (LABEL_1) - Confidence: 0.58
##rta (LABEL_0) - Confidence: 0.56
, indon (LABEL_1) - Confidence: 0.59
##esi (LABEL_0) - Confidence: 0.57
##a. (LABEL_1) - Confidence: 0.62
( 3 ) (LABEL_0) - Confidence: 0.52
master program in biomedical (LABEL_1) - Confidence: 0.55
sciences (LABEL_0) - Confidence: 0.51
, (LABEL_1) - Confidence: 0.69
faculty (LABEL_0) - Confidence: 0.60
of medicine, univers (LABEL_1) - Confidence: 0.59
##itas (LABEL_0) - Confidence: 0.52
indon (LABEL_1) - Confidence: 0.52
##esi (LABEL_0) - Confidence: 0.63
##a, (LABEL_1) - Confidence: 0.59
j (LABEL_0) - Confidence: 0.52
##aka (LABEL_1) - Confidence: 0.55
##rta (LABEL_0) - Confidence: 0.58
, (LABEL_1) - Confidence: 0.69
in (LABEL_0) - Confidence: 0.51
##don (LABEL_1) - Confidence: 0.52
##esi (LABEL_0) - Confidence: 0.59
##a. (LABEL_1) - Confidence: 0.60
( 4 (LABEL_0) - Confidence: 0.55
) drug development research cluster, indon (LABEL_1) - Confidence: 0.55
##esi (LABEL_0) - Confidence: 0.58
##an medical (LABEL_1) - Confidence: 0.63
education (LABEL_0) - Confidence: 0.52
and research instit (LABEL_1) - Confidence: 0.60

----------------------------------------

--- SUMMARY for Chunk 11 ---
 The p53 signaling pathway plays a critical role in regulating the cell cycle, iopoptosis, and senescence, making it a key target in cancer research . The aim of the study was to investigate the effects of an ethanol extract from the stem of Ziziphus nummularia on the proliferation and expression of genes involved in the p53 pathway in MCF-7 breast cancer cells .

--- ENTITIES for Chunk 11 ---
ute, (LABEL_1) - Confidence: 0.57
faculty (LABEL_0) - Confidence: 0.60
of medicine, univers (LABEL_1) - Confidence: 0.63
##itas in (LABEL_0) - Confidence: 0.52
##don (LABEL_1) - Confidence: 0.52
##esi (LABEL_0) - Confidence: 0.57
##a, jakarta, (LABEL_1) - Confidence: 0.60
in (LABEL_0) - Confidence: 0.53
##don (LABEL_1) - Confidence: 0.53
##esi (LABEL_0) - Confidence: 0.55
##a. ( (LABEL_1) - Confidence: 0.59
5 (LABEL_0) - Confidence: 0.55
) department of pharmaceutical chemistry, (LABEL_1) - Confidence: 0.64
faculty (LABEL_0) - Confidence: 0.59
of pharmacy, univers (LABEL_1) - Confidence: 0.61
##iti (LABEL_0) - Confidence: 0.60
malaya, kuala lumpur, malay (LABEL_1) - Confidence: 0.60
##sia (LABEL_0) - Confidence: 0.51
. the p53 signaling pathway (LABEL_1) - Confidence: 0.60
plays (LABEL_0) - Confidence: 0.54
a critical (LABEL_1) - Confidence: 0.54
role in (LABEL_0) - Confidence: 0.55
regulating the cell (LABEL_1) - Confidence: 0.59
cycle (LABEL_0) - Confidence: 0.53
, a (LABEL_1) - Confidence: 0.59
##poptosis (LABEL_0) - Confidence: 0.53
, and (LABEL_1) - Confidence: 0.55
senes (LABEL_0) - Confidence: 0.54
##cence, making it (LABEL_1) - Confidence: 0.55
a (LABEL_0) - Confidence: 0.51
key (LABEL_1) - Confidence: 0.53
target (LABEL_0) - Confidence: 0.59
in cancer research. the aim of this study was to investigate the effects of an ethanol extract from the stem of ziziphus nummular (LABEL_1) - Confidence: 0.61
##ia (LABEL_0) - Confidence: 0.51
on the (LABEL_1) - Confidence: 0.61
proliferation (LABEL_0) - Confidence: 0.53
and expression of genes involved in the p53 pathway in mcf - 7 breast cancer cells. to achieve this, (LABEL_1) - Confidence: 0.60
real (LABEL_0) - Confidence: 0.63
- (LABEL_1) - Confidence: 0.56
time (LABEL_0) - Confidence: 0.58
quantitative pcr ( (LABEL_1) - Confidence: 0.57
r (LABEL_0) - Confidence: 0.53
##t - qpcr ) was used to evaluate the mrna (LABEL_1) - Confidence: 0.57
expression (LABEL_0) - Confidence: 0.51
of downstream genes linked to cell (LABEL_1) - Confidence: 0.55
cycle (LABEL_0) - Confidence: 0.51
and se (LABEL_1) - Confidence: 0.54
##nes (LABEL_0) - Confidence: 0.51
##cence, including cyce or ccnel, rbll, and e2f1. molecular docking simulations using molegro virtual docker ( mvd ) were also performed to assess the potential inhibitory activity of metabolite compounds from z. nummularia stem against p53 - regulating kinase ( tp53rk ). the results showed that the i (LABEL_1) - Confidence: 0.61
##c (LABEL_0) - Confidence: 0.54
##50 value (LABEL_1) - Confidence: 0.56

----------------------------------------

--- SUMMARY for Chunk 12 ---
 The ethanol extract of Z. nummularia stem ethanol extract against MCF-7 cells was 38.27âÂ±â0.72âÎ¼g/mL . The results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell cycle .

--- ENTITIES for Chunk 12 ---
of z. nummularia stem ethanol extract against mcf - 7 cells was 38. 27 Â± (LABEL_1) - Confidence: 0.62
0 (LABEL_0) - Confidence: 0.54
. 72 Î¼g / ml. the results also revealed a reduction in the expression of downstream genes linked to cell senescence and the cell (LABEL_1) - Confidence: 0.60
cycle (LABEL_0) - Confidence: 0.52
: cyce or ccne1 ( (LABEL_1) - Confidence: 0.59
p = 0. 01 (LABEL_0) - Confidence: 0.56
##1 ), rbl1 ( (LABEL_1) - Confidence: 0.60
p = 0 (LABEL_0) - Confidence: 0.61
. (LABEL_1) - Confidence: 0.57
00 (LABEL_0) - Confidence: 0.53
##8 ), and e2f1 ( (LABEL_1) - Confidence: 0.60
p = 0 (LABEL_0) - Confidence: 0.62
. (LABEL_1) - Confidence: 0.58
00 (LABEL_0) - Confidence: 0.55
##5 ), which was observed through rt - qp (LABEL_1) - Confidence: 0.58
##c (LABEL_0) - Confidence: 0.56
##r analysis of mrna expression. this fact indicated that the inhibitory effects on proliferation by the ethanol extract of z. nummularia stem (LABEL_1) - Confidence: 0.61
might (LABEL_0) - Confidence: 0.57
occur via pathways associated with cell senescence and cell (LABEL_1) - Confidence: 0.58
cycle (LABEL_0) - Confidence: 0.53
arrest. molecular docking results of metabolite compounds from z. n (LABEL_1) - Confidence: 0.60
##um (LABEL_0) - Confidence: 0.51
##mularia stem suggested that (LABEL_1) - Confidence: 0.57
squal (LABEL_0) - Confidence: 0.53
##ene ( (LABEL_1) - Confidence: 0.58
rerank score (LABEL_0) - Confidence: 0.53
- 112. 70 k (LABEL_1) - Confidence: 0.56
##j (LABEL_0) - Confidence: 0.55
/ mol ), and nummular (LABEL_1) - Confidence: 0.57
##ine (LABEL_0) - Confidence: 0.57
b ( (LABEL_1) - Confidence: 0.55
rerank score (LABEL_0) - Confidence: 0.54
- 110. 68 k (LABEL_1) - Confidence: 0.57
##j (LABEL_0) - Confidence: 0.55
/ mol ) had potential as tp53rk inhibitors. these rerank scores were smaller compared to the (LABEL_1) - Confidence: 0.58
re (LABEL_0) - Confidence: 0.55
##rank (LABEL_1) - Confidence: 0.51
score (LABEL_0) - Confidence: 0.50
of ad (LABEL_1) - Confidence: 0.57
##enyl (LABEL_0) - Confidence: 0.54
- (LABEL_1) - Confidence: 0.50
im (LABEL_0) - Confidence: 0.56
##idodiph (LABEL_1) - Confidence: 0.58
##osphate (LABEL_0) - Confidence: 0.54
( amp - pnp ), (LABEL_1) - Confidence: 0.58
which was (LABEL_0) - Confidence: 0.54
the native (LABEL_1) - Confidence: 0.57
ligan (LABEL_0) - Confidence: 0.52
##d of tp53rk, as confirmed by molecular dynamics analysis. these in silico results were confirmed (LABEL_1) - Confidence: 0.62
by (LABEL_0) - Confidence: 0.52
the decrease in p21 ( (LABEL_1) - Confidence: 0.54
c (LABEL_0) - Confidence: 0.52
##d (LABEL_1) - Confidence: 0.52

----------------------------------------

--- SUMMARY for Chunk 13 ---
 The anti-proliferative effects of the extract from Z. nummularia stem on breast cancer cells occurred by affecting cell cycle-related genes and inhibiting apoptosis protection mediated by overexpression of p21 (CDKN1A) through p53 activity .

--- ENTITIES for Chunk 13 ---
kn1a ) mrna expression. in conclusion, the anti - pro (LABEL_1) - Confidence: 0.61
##life (LABEL_0) - Confidence: 0.52
##rative effects of the ethanol extract from z. nummularia stem on breast cancer cells occurred by affecting cell cycle - related genes and inhibiting apoptosis protection mediated by overex (LABEL_1) - Confidence: 0.61
##press (LABEL_0) - Confidence: 0.53
##ion of p21 ( cdkn1a ) through p53 activity. Â© 2025 the author ( s ). (LABEL_1) - Confidence: 0.61
doi (LABEL_0) - Confidence: 0.60
: (LABEL_1) - Confidence: 0.73
10 (LABEL_0) - Confidence: 0.58
. (LABEL_1) - Confidence: 0.59
52 (LABEL_0) - Confidence: 0.55
##225 / narra. v5i1. 1382 pmcid : pmc12059826 pmid : 40352177 [ indexed for medline ] conflict of interest statement : the authors declare no conflict of interest. 5. j biomol struct dyn. 2025 may 12 : 1 - 21. (LABEL_1) - Confidence: 0.63
doi (LABEL_0) - Confidence: 0.58
: (LABEL_1) - Confidence: 0.69
10 (LABEL_0) - Confidence: 0.60
. 1080 / 07391102. 2025. 2499950. online ahead of print. bioinformatics approach reveals the modulatory role of (LABEL_1) - Confidence: 0.63
jun (LABEL_0) - Confidence: 0.56
in atorvas (LABEL_1) - Confidence: 0.57
##tat (LABEL_0) - Confidence: 0.61
##in - mediated anti - (LABEL_1) - Confidence: 0.63
breast (LABEL_0) - Confidence: 0.51
cancer effects. foda my ( 1 ), al - shun sa (LABEL_1) - Confidence: 0.59
( (LABEL_0) - Confidence: 0.50
1 ), abdelkrim g (LABEL_1) - Confidence: 0.57
( (LABEL_0) - Confidence: 0.53
2 ), salem ml ( 3 ), salah na ( 1 ), el - khawaga oy ( 1 ). author information : ( (LABEL_1) - Confidence: 0.59
1 (LABEL_0) - Confidence: 0.51
) biochemistry division, chemistry department, (LABEL_1) - Confidence: 0.60
faculty (LABEL_0) - Confidence: 0.57
of science, mansoura university, mansoura, egypt. ( 2 ) laboratory of chemistry, synthesis, properties and applications ( lcspa ), university (LABEL_1) - Confidence: 0.61

----------------------------------------

--- SUMMARY for Chunk 14 ---
 Atorvastatin exhibited notable predicted cytotoxicity against breast cancer lines . JUN was identified as the hub gene in the . protein-protein interaction (PPI) network and was shown to be responsive to Â vastin in breast cancer .

--- ENTITIES for Chunk 14 ---
of saida, saida, algeria. ( 3 ) immunology and biotechnology unit, department of zoology, (LABEL_1) - Confidence: 0.64
faculty (LABEL_0) - Confidence: 0.54
of science, and center of excellence in cancer research, tanta university, tanta, egypt. atorvas (LABEL_1) - Confidence: 0.63
##tat (LABEL_0) - Confidence: 0.57
##in, (LABEL_1) - Confidence: 0.52
a (LABEL_0) - Confidence: 0.56
widely (LABEL_1) - Confidence: 0.60
prescribed chole (LABEL_0) - Confidence: 0.53
##ster (LABEL_1) - Confidence: 0.50
##ol (LABEL_0) - Confidence: 0.51
- (LABEL_1) - Confidence: 0.53
lowering (LABEL_0) - Confidence: 0.51
drug, (LABEL_1) - Confidence: 0.54
has recently (LABEL_0) - Confidence: 0.54
shown potential anti (LABEL_1) - Confidence: 0.57
##can (LABEL_0) - Confidence: 0.53
##cer effects. (LABEL_1) - Confidence: 0.60
however (LABEL_0) - Confidence: 0.54
, its influence on gene (LABEL_1) - Confidence: 0.53
expression (LABEL_0) - Confidence: 0.52
and its biological functions (LABEL_1) - Confidence: 0.54
in (LABEL_0) - Confidence: 0.55
cancer, (LABEL_1) - Confidence: 0.57
in (LABEL_0) - Confidence: 0.53
particular breast cancer, (LABEL_1) - Confidence: 0.54
still (LABEL_0) - Confidence: 0.52
unclear. we aim to identify the dysre (LABEL_1) - Confidence: 0.60
##gu (LABEL_0) - Confidence: 0.50
##lated (LABEL_1) - Confidence: 0.55
genes (LABEL_0) - Confidence: 0.50
associated with atorvas (LABEL_1) - Confidence: 0.61
##tat (LABEL_0) - Confidence: 0.53
##in treatment and the main players in their biological network. a total of 103 differentially (LABEL_1) - Confidence: 0.57
expressed (LABEL_0) - Confidence: 0.55
genes ( degs ) in the unified signature were identified, and the functional enrichment analysis suggested their relation to multiple cancer - (LABEL_1) - Confidence: 0.58
related pathways (LABEL_0) - Confidence: 0.51
. (LABEL_1) - Confidence: 0.54
jun (LABEL_0) - Confidence: 0.58
was identified as the (LABEL_1) - Confidence: 0.54
hub gene (LABEL_0) - Confidence: 0.55
in the protein - protein (LABEL_1) - Confidence: 0.53
interaction (LABEL_0) - Confidence: 0.51
( (LABEL_1) - Confidence: 0.53
ppi (LABEL_0) - Confidence: 0.53
) network and (LABEL_1) - Confidence: 0.57
was (LABEL_0) - Confidence: 0.50
shown (LABEL_1) - Confidence: 0.52
to be responsive to (LABEL_0) - Confidence: 0.58
atorvas (LABEL_1) - Confidence: 0.58
##tat (LABEL_0) - Confidence: 0.57
##in (LABEL_1) - Confidence: 0.52
in breast (LABEL_0) - Confidence: 0.54
cancer. atorvas (LABEL_1) - Confidence: 0.58
##tat (LABEL_0) - Confidence: 0.53
##in exhibited notable predicted cyt (LABEL_1) - Confidence: 0.59
##oto (LABEL_0) - Confidence: 0.54
##xicity against breast cancer lines, with the (LABEL_1) - Confidence: 0.61

----------------------------------------

--- SUMMARY for Chunk 15 ---
 Atorvastatin activity positively  correlated with JUN expression . JUN protein expression inversely correlated with cancer progression . Higher JUN expression was linked with better survival outcomes .

--- ENTITIES for Chunk 15 ---
activity positively correlated with (LABEL_1) - Confidence: 0.59
jun (LABEL_0) - Confidence: 0.55
expression. (LABEL_1) - Confidence: 0.60
jun (LABEL_0) - Confidence: 0.56
was (LABEL_1) - Confidence: 0.52
significantly (LABEL_0) - Confidence: 0.52
down (LABEL_1) - Confidence: 0.50
##regulated (LABEL_0) - Confidence: 0.53
in breast cancer expression inversely correlated with cancer progression, whereas higher j (LABEL_1) - Confidence: 0.59
##un (LABEL_0) - Confidence: 0.57
expression was linked with better survival outcomes. atorvas (LABEL_1) - Confidence: 0.57
##tatin (LABEL_0) - Confidence: 0.53
may directly interact with (LABEL_1) - Confidence: 0.57
jun (LABEL_0) - Confidence: 0.54
protein forming a more compact and stable conformation. these findings demystify the potential therapeutic mechanism of atorvas (LABEL_1) - Confidence: 0.58
##tatin (LABEL_0) - Confidence: 0.55
in breast cancer, possibly by fine tuning of (LABEL_1) - Confidence: 0.57
jun (LABEL_0) - Confidence: 0.57
expression. as such, (LABEL_1) - Confidence: 0.62
jun might (LABEL_0) - Confidence: 0.56
serve as a valuable pro (LABEL_1) - Confidence: 0.58
##gno (LABEL_0) - Confidence: 0.50
##stic biomarker in breast cancer. (LABEL_1) - Confidence: 0.57
doi (LABEL_0) - Confidence: 0.61
: (LABEL_1) - Confidence: 0.72
10 (LABEL_0) - Confidence: 0.62
. 108 (LABEL_1) - Confidence: 0.60
##0 (LABEL_0) - Confidence: 0.52
/ 07391102. 2025. 2499950 pmid : 40351185 6. (LABEL_1) - Confidence: 0.65
bio (LABEL_0) - Confidence: 0.51
##mol biomed. 2025 may 9. (LABEL_1) - Confidence: 0.63
doi (LABEL_0) - Confidence: 0.62
: (LABEL_1) - Confidence: 0.69
10 (LABEL_0) - Confidence: 0.58
. 17305 / (LABEL_1) - Confidence: 0.65
b (LABEL_0) - Confidence: 0.52
##b. 2025. 12333. online ahead of print. lncrna interactomes and co - methylation in breast cancer regulation. filippova ea ( 1 ), (LABEL_1) - Confidence: 0.61
pro (LABEL_0) - Confidence: 0.53
##nina (LABEL_1) - Confidence: 0.59
i (LABEL_0) - Confidence: 0.53
##v ( 2 ), (LABEL_1) - Confidence: 0.58
luki (LABEL_0) - Confidence: 0.52
##na ss ( 1 ), burdennyy am ( 1 ), kazubskaya tp ( 3 ), (LABEL_1) - Confidence: 0.59
logino (LABEL_0) - Confidence: 0.52
##v vi ( 1 ), braga ea ( 1 ). author information : ( 1 ) institute of general pathology and pathophysiology, moscow, russia. ( 2 ) n. m. emanuel institute of bioche (LABEL_1) - Confidence: 0.63

----------------------------------------

--- SUMMARY for Chunk 16 ---
 The key molecular mechanisms underlying breast cancer's development remain incompletely understood . We identified seven differentially expressed (DE) lncRNAs . Four of these-ADAMTS9-AS2, HAND2-AS1, HOTAIRM1, and MEG3-were prioritized through evaluation . qPCR confirmed their downregulation .

--- ENTITIES for Chunk 16 ---
mical physics, russian academy of science, moscow, russia. ( 3 ) n. n. blokhin national medical research center of oncology, the (LABEL_1) - Confidence: 0.61
ministry (LABEL_0) - Confidence: 0.52
of health of russia, moscow, russ (LABEL_1) - Confidence: 0.62
##ia (LABEL_0) - Confidence: 0.52
. breast cancer is the most commonly (LABEL_1) - Confidence: 0.57
diagnosed (LABEL_0) - Confidence: 0.53
mali (LABEL_1) - Confidence: 0.58
##gna (LABEL_0) - Confidence: 0.62
##ncy in women. despite advances in (LABEL_1) - Confidence: 0.56
diagnostic (LABEL_0) - Confidence: 0.51
##s and (LABEL_1) - Confidence: 0.63
treatment (LABEL_0) - Confidence: 0.51
, the key molecular mechanisms underlying its development remain (LABEL_1) - Confidence: 0.60
incomplete (LABEL_0) - Confidence: 0.52
##ly understood. this study aimed to identify novel l (LABEL_1) - Confidence: 0.62
##ncrna (LABEL_0) - Confidence: 0.54
- mi (LABEL_1) - Confidence: 0.57
##rna (LABEL_0) - Confidence: 0.56
- (LABEL_1) - Confidence: 0.57
mrna (LABEL_0) - Confidence: 0.51
regulatory networks potentially involved in breast cancer - associated signaling pathways. using an rtÂ² lnc (LABEL_1) - Confidence: 0.60
##rna (LABEL_0) - Confidence: 0.51
pc (LABEL_1) - Confidence: 0.61
##r (LABEL_0) - Confidence: 0.53
array and bioinformatic analysis, we identified seven differentially (LABEL_1) - Confidence: 0.63
expressed (LABEL_0) - Confidence: 0.52
( de ) l (LABEL_1) - Confidence: 0.59
##ncrna (LABEL_0) - Confidence: 0.53
##s. (LABEL_1) - Confidence: 0.61
four (LABEL_0) - Confidence: 0.56
of these - adamts9 - as2, hand2 - as1, hotairm1, and meg3 - were (LABEL_1) - Confidence: 0.59
prioriti (LABEL_0) - Confidence: 0.54
##zed through integrative evaluation. qp (LABEL_1) - Confidence: 0.60
##c (LABEL_0) - Confidence: 0.56
##r confirmed their down (LABEL_1) - Confidence: 0.55
##re (LABEL_0) - Confidence: 0.52
##gulation and aberrant methylation in breast tumor samples. we observed significant positive expression correlations between the pairs adamts9 - as2 - meg3, hand2 - as1 - meg3, and hotairm1 - meg3, as well as co - methylation among ada (LABEL_1) - Confidence: 0.60

----------------------------------------

--- SUMMARY for Chunk 17 ---
 TCF7L2 is a common target gene of these lncRNAs, which is involved in the Wnt, Hippo, and MAPK signaling pathways . We also identified several miRNAs interacting with ADAMTS9-AS2 . These findings suggest their involvement in key signaling networks in breast cancer .

--- ENTITIES for Chunk 17 ---
mts9 - as2 - hand2 - as (LABEL_1) - Confidence: 0.60
##1 (LABEL_0) - Confidence: 0.51
, adamts9 - as2 - hotairm1, hand2 - as1 - meg3, and (LABEL_1) - Confidence: 0.60
hand (LABEL_0) - Confidence: 0.51
##2 - as1 - hotairm1, suggesting coordinated regulation. these findings are consistent with data from gepia 2. 0. bioinformatic prediction identified tcf7l2 as (LABEL_1) - Confidence: 0.61
a (LABEL_0) - Confidence: 0.54
common (LABEL_1) - Confidence: 0.58
target gene (LABEL_0) - Confidence: 0.57
of these lnc (LABEL_1) - Confidence: 0.62
##rna (LABEL_0) - Confidence: 0.52
##s, (LABEL_1) - Confidence: 0.56
which is involved in (LABEL_0) - Confidence: 0.53
the wnt, hippo, and mapk signaling pathways. we also identified several mirnas interacting with adamts9 - as2. in a cohort of 50 tumor samples, we confirmed inverse associations between adamts9 - as2 expression and levels of (LABEL_1) - Confidence: 0.62
mi (LABEL_0) - Confidence: 0.53
##r - 106a - (LABEL_1) - Confidence: 0.56
5p (LABEL_0) - Confidence: 0.54
( rs (LABEL_1) - Confidence: 0.59
= (LABEL_0) - Confidence: 0.54
- 0. 46, (LABEL_1) - Confidence: 0.62
p = 0. (LABEL_0) - Confidence: 0.59
03 ) and (LABEL_1) - Confidence: 0.55
mi (LABEL_0) - Confidence: 0.50
##r - 17 (LABEL_1) - Confidence: 0.59
- 5p (LABEL_0) - Confidence: 0.52
( rs (LABEL_1) - Confidence: 0.59
= (LABEL_0) - Confidence: 0.54
- 0. 41, (LABEL_1) - Confidence: 0.61
p = 0 (LABEL_0) - Confidence: 0.60
. 04 ). collectively, these findings reveal novel co - (LABEL_1) - Confidence: 0.62
regulated (LABEL_0) - Confidence: 0.56
lncrna - mirna axes and suggest their involvement in key signaling networks in breast cancer, providing a foundation for future functional studies and potential therapeutic targeting. (LABEL_1) - Confidence: 0.58
doi (LABEL_0) - Confidence: 0.57
: (LABEL_1) - Confidence: 0.72
10 (LABEL_0) - Confidence: 0.56
. 17305 / bb. 2025. 12333 pmid : 40350996 7. j immunother cancer. 2025 may 11 ; 13 ( (LABEL_1) - Confidence: 0.65
5 (LABEL_0) - Confidence: 0.51
) : e010548. (LABEL_1) - Confidence: 0.65
doi (LABEL_0) - Confidence: 0.62
: (LABEL_1) - Confidence: 0.69
10 (LABEL_0) - Confidence: 0.63
. (LABEL_1) - Confidence: 0.55
113 (LABEL_0) - Confidence: 0.52
##6 / jitc - 2024 - 010548. the cold immunological landscape of atm - deficient c (LABEL_1) - Confidence: 0.63

----------------------------------------

--- SUMMARY for Chunk 18 ---
 The author of this article has published an article on the topic of cancer research at the Memorial Sloan Kettering Cancer Center in New York, New York . The study was published in the journal Human Oncureure.com .

--- ENTITIES for Chunk 18 ---
ancers. sinha s ( # ) ( 1 ), ng v ( # ) ( 1 ), novaj a ( 1 ), zhu y ( 2 ), yazaki s ( 1 ), pei x ( 1 ), derakhshan f ( 3 ), pareja f ( 2 ), setton (LABEL_1) - Confidence: 0.59
j (LABEL_0) - Confidence: 0.50
( 1 ), na (LABEL_1) - Confidence: 0.54
##ulin (LABEL_0) - Confidence: 0.54
f ( (LABEL_1) - Confidence: 0.54
4 (LABEL_0) - Confidence: 0.51
), beltran - v (LABEL_1) - Confidence: 0.56
##isied (LABEL_0) - Confidence: 0.56
##o m ( (LABEL_1) - Confidence: 0.53
4 (LABEL_0) - Confidence: 0.53
), shin e ( 1 ), longhini alf ( (LABEL_1) - Confidence: 0.56
5 (LABEL_0) - Confidence: 0.54
), gardner r ( 5 ), ma j ( 1 ), ma k ( 1 ), roulston a ( 6 ), morris s ( 6 ), koehler m ( 7 ), powell s ( 1 ), rosen e ( 8 ), galluzzi l ( 4 ), (LABEL_1) - Confidence: 0.61
re (LABEL_0) - Confidence: 0.54
##is - filho j ( 2 ), khan a ( 9 ), riaz n ( 9 ). author information : (LABEL_1) - Confidence: 0.59
( 1 (LABEL_0) - Confidence: 0.52
) department of radiation oncology, memorial sloan (LABEL_1) - Confidence: 0.59
k (LABEL_0) - Confidence: 0.51
##ettering cancer (LABEL_1) - Confidence: 0.55
center (LABEL_0) - Confidence: 0.51
, (LABEL_1) - Confidence: 0.68
new york (LABEL_0) - Confidence: 0.57
, (LABEL_1) - Confidence: 0.66
new yo (LABEL_0) - Confidence: 0.57
##rk, (LABEL_1) - Confidence: 0.61
us (LABEL_0) - Confidence: 0.52
##a. (LABEL_1) - Confidence: 0.59
( (LABEL_0) - Confidence: 0.52
2 ) department of pathology, memorial sloan kettering cancer center, (LABEL_1) - Confidence: 0.59
new yo (LABEL_0) - Confidence: 0.57
##rk, new (LABEL_1) - Confidence: 0.57
yo (LABEL_0) - Confidence: 0.59
##rk, usa. (LABEL_1) - Confidence: 0.59
( 3 (LABEL_0) - Confidence: 0.53
) department of pathology, co (LABEL_1) - Confidence: 0.62
##lum (LABEL_0) - Confidence: 0.50
##bia university, (LABEL_1) - Confidence: 0.60
new yo (LABEL_0) - Confidence: 0.56
##rk, (LABEL_1) - Confidence: 0.61
new yo (LABEL_0) - Confidence: 0.56
##rk, (LABEL_1) - Confidence: 0.62
us (LABEL_0) - Confidence: 0.51
##a. (LABEL_1) - Confidence: 0.60
( 4 ) (LABEL_0) - Confidence: 0.57
cancer signaling and microenvironment program, fox chase cancer center, philadelphia, pa, (LABEL_1) - Confidence: 0.61
us (LABEL_0) - Confidence: 0.51
##a. (LABEL_1) - Confidence: 0.58
( 5 ) memorial (LABEL_0) - Confidence: 0.58
sloan (LABEL_1) - Confidence: 0.56
kette (LABEL_0) - Confidence: 0.51
##ring cancer (LABEL_1) - Confidence: 0.58
center (LABEL_0) - Confidence: 0.52
, (LABEL_1) - Confidence: 0.68
new york (LABEL_0) - Confidence: 0.56
, (LABEL_1) - Confidence: 0.65
new yo (LABEL_0) - Confidence: 0.57
##rk, (LABEL_1) - Confidence: 0.60
us (LABEL_0) - Confidence: 0.54
##a. (LABEL_1) - Confidence: 0.58
( 6 (LABEL_0) - Confidence: 0.57
) (LABEL_1) - Confidence: 0.53
re (LABEL_0) - Confidence: 0.54
##pare therapeutics, saint - (LABEL_1) - Confidence: 0.59
la (LABEL_0) - Confidence: 0.55
##urent, quebec, canada. ( 7 ) (LABEL_1) - Confidence: 0.57
re (LABEL_0) - Confidence: 0.52
##pare therapeutics, boston, massachusetts, usa. ( 8 ) mskcc, new (LABEL_1) - Confidence: 0.61
yo (LABEL_0) - Confidence: 0.57
##rk, (LABEL_1) - Confidence: 0.61
new yo (LABEL_0) - Confidence: 0.53
##rk, (LABEL_1) - Confidence: 0.61
us (LABEL_0) - Confidence: 0.51
##a. ( (LABEL_1) - Confidence: 0.58
9 (LABEL_0) - Confidence: 0.50
) (LABEL_1) - Confidence: 0.53
department (LABEL_0) - Confidence: 0.52
of radiation oncology, memorial sloan ket (LABEL_1) - Confidence: 0.60

----------------------------------------

--- SUMMARY for Chunk 19 ---
 Ataxia telangiectasia mutated (ATM) is a central regulator of DNA double-strand break repair . ATM is frequently affected by somatic or germline mutations in various cancer types, including breast, Prostate, pancreatic, and lung cancer . The consequences of ATM loss on immunogenicity are poorly understood .

--- ENTITIES for Chunk 19 ---
tering cancer center, new york, new york, usa riazn @ msk (LABEL_1) - Confidence: 0.57
##cc (LABEL_0) - Confidence: 0.55
. org khana7 @ msk (LABEL_1) - Confidence: 0.59
##cc (LABEL_0) - Confidence: 0.55
. org. ( # ) contributed equally background : mutations in genes encoding dna repair factors, which facilitate mismatch repair, homologous recombination, or dna (LABEL_1) - Confidence: 0.62
polymer (LABEL_0) - Confidence: 0.51
##ase functions, (LABEL_1) - Confidence: 0.63
are known (LABEL_0) - Confidence: 0.56
to enhance tumor immunogenicity. ataxia telangiectasia (LABEL_1) - Confidence: 0.59
mutated (LABEL_0) - Confidence: 0.56
( atm ) is a central (LABEL_1) - Confidence: 0.56
regulator (LABEL_0) - Confidence: 0.57
of dna double - strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. however, the consequences of atm loss on tumor immunogenicity are poorly understood. (LABEL_1) - Confidence: 0.59
methods (LABEL_0) - Confidence: 0.56
: we generated isogenic atm - null models using (LABEL_1) - Confidence: 0.67
crisp (LABEL_0) - Confidence: 0.54
##r in murine triple - (LABEL_1) - Confidence: 0.60
negative (LABEL_0) - Confidence: 0.52
breast ( 4t1 ) and (LABEL_1) - Confidence: 0.57
colorec (LABEL_0) - Confidence: 0.54
##tal ( c (LABEL_1) - Confidence: 0.56
##t (LABEL_0) - Confidence: 0.51
##26 ) cancer cell lines. atm inactivation was confirmed by pcr and western blot. immune cell infi (LABEL_1) - Confidence: 0.58
##lt (LABEL_0) - Confidence: 0.52
##rates were assessed by flow c (LABEL_1) - Confidence: 0.60
##yt (LABEL_0) - Confidence: 0.52
##ometry and immunohis (LABEL_1) - Confidence: 0.59
##to (LABEL_0) - Confidence: 0.52
##chemistry in both murine tumors and human samples from breast and lung cancers ( via the cancer genome atla (LABEL_1) - Confidence: 0.63

----------------------------------------

--- SUMMARY for Chunk 20 ---
 In vitro, the impact of ATM loss on tumor growth and immune checkpoint blockade (anti-programmed cell death protein-1) was evaluated . Assessing various DNA-damaging agents in Atm null tumors revealed a differential activation of type I Â interferon (IFN) signaling .

--- ENTITIES for Chunk 20 ---
s and institutional cohorts ). in vivo, the impact of atm loss on tumor growth and response to immune (LABEL_1) - Confidence: 0.61
check (LABEL_0) - Confidence: 0.54
##point blockade ( anti - programmed cell death protein - 1 ( pd (LABEL_1) - Confidence: 0.56
- (LABEL_0) - Confidence: 0.52
1 ) ) was evaluated. furthermore, we compared the effects of different dna - damaging agents - including an atr (LABEL_1) - Confidence: 0.62
inhibitor (LABEL_0) - Confidence: 0.53
( rp - 350 (LABEL_1) - Confidence: 0.55
##0 (LABEL_0) - Confidence: 0.58
), a parp (LABEL_1) - Confidence: 0.56
inhibitor (LABEL_0) - Confidence: 0.56
( olapari (LABEL_1) - Confidence: 0.54
##b (LABEL_0) - Confidence: 0.54
), and the top (LABEL_1) - Confidence: 0.58
##oisomer (LABEL_0) - Confidence: 0.54
##ase ii (LABEL_1) - Confidence: 0.53
inhibitor (LABEL_0) - Confidence: 0.50
etop (LABEL_1) - Confidence: 0.58
##os (LABEL_0) - Confidence: 0.66
##ide - on (LABEL_1) - Confidence: 0.62
interfer (LABEL_0) - Confidence: 0.55
##on - stimulated gene ( (LABEL_1) - Confidence: 0.62
is (LABEL_0) - Confidence: 0.50
##g ) expression and immune modulation. results : we find that - in contrast to other dna repair defects - atm deficiency ( 1 ) (LABEL_1) - Confidence: 0.62
fails (LABEL_0) - Confidence: 0.50
to encourage immune effector cell in (LABEL_1) - Confidence: 0.58
##fi (LABEL_0) - Confidence: 0.55
##ltration into tumors, and ( 2 ) (LABEL_1) - Confidence: 0.61
does (LABEL_0) - Confidence: 0.53
not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with atr (LABEL_1) - Confidence: 0.59
in (LABEL_0) - Confidence: 0.54
##hibition. assessing various dna - damaging agents in atm null tumors revealed a differential activation of (LABEL_1) - Confidence: 0.62
type (LABEL_0) - Confidence: 0.56
i (LABEL_1) - Confidence: 0.54
interfer (LABEL_0) - Confidence: 0.59
##on ( (LABEL_1) - Confidence: 0.58
if (LABEL_0) - Confidence: 0.69
##n ) signaling, with etop (LABEL_1) - Confidence: 0.61
##os (LABEL_0) - Confidence: 0.61
##ide, a top (LABEL_1) - Confidence: 0.58
##oisomer (LABEL_0) - Confidence: 0.54
##ase ii (LABEL_1) - Confidence: 0.52
inhibitor (LABEL_0) - Confidence: 0.50
, emerging as the strongest activator of (LABEL_1) - Confidence: 0.61
is (LABEL_0) - Confidence: 0.52
##g under these conditions. yet, pd - 1 - targeted immune check (LABEL_1) - Confidence: 0.62

----------------------------------------

--- SUMMARY for Chunk 21 ---
 Atm-null syngeneic tumor models did not increase tumor igenicity or immunogenicity . ATR blockade does not bolster the therapeutic therapeutic activity of etoposide in ATR models . The results have important implications for the design of novel combination therapies for ATM null tumors .

--- ENTITIES for Chunk 21 ---
point blockade does not bolster the therapeutic activity of etop (LABEL_1) - Confidence: 0.62
##os (LABEL_0) - Confidence: 0.53
##ide in atm - null syngeneic tumor models, nor (LABEL_1) - Confidence: 0.64
does (LABEL_0) - Confidence: 0.52
it modify the tumor microenvironment, suggesting that type i ifn signaling alone is insufficient to overcome immunosuppression in immunologically cold atm null neoplasms. (LABEL_1) - Confidence: 0.61
conclusions (LABEL_0) - Confidence: 0.52
: atm deficiency, while com (LABEL_1) - Confidence: 0.62
##p (LABEL_0) - Confidence: 0.51
##romising dna repair and enhancing sensitivity to radiation and atr inhibition, (LABEL_1) - Confidence: 0.58
does (LABEL_0) - Confidence: 0.55
not increase tumor antigenicity or immunogenicity. altogether, our results have important implications for the design of novel combination therapies for atm null tumors and highlight the importance of antigenicity in the immunological consequences of defective dna repair. Â© author ( s ) ( or their employer ( s ) ) 2025. re - use permitted under cc by - n (LABEL_1) - Confidence: 0.62
##c (LABEL_0) - Confidence: 0.56
. no commercial re - (LABEL_1) - Confidence: 0.64
use (LABEL_0) - Confidence: 0.51
. see rights and permissions. published by bmj group. (LABEL_1) - Confidence: 0.63
doi (LABEL_0) - Confidence: 0.55
: (LABEL_1) - Confidence: 0.69
10. 113 (LABEL_0) - Confidence: 0.57
##6 / jitc - 2024 - 010548 pmid : 40350205 [ (LABEL_1) - Confidence: 0.63
index (LABEL_0) - Confidence: 0.56
##ed for medline ] conflict of interest statement : competing (LABEL_1) - Confidence: 0.62
interests (LABEL_0) - Confidence: 0.56
: nr receives research support from bm (LABEL_1) - Confidence: 0.60

----------------------------------------

--- SUMMARY for Chunk 22 ---
 LG is/has been  holding research contracts with Lytix Biopharma, Promontory and Onxeo . LG has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, Pfizer, Repare Therapuetics, and Invitae .

--- ENTITIES for Chunk 22 ---
s, pfizer, repare therapuetics, and in (LABEL_1) - Confidence: 0.62
##vita (LABEL_0) - Confidence: 0.50
##e. lg is / (LABEL_1) - Confidence: 0.62
has (LABEL_0) - Confidence: 0.54
been holding research (LABEL_1) - Confidence: 0.57
contracts (LABEL_0) - Confidence: 0.54
with lytix biopharma, promontory and onxeo, (LABEL_1) - Confidence: 0.61
has (LABEL_0) - Confidence: 0.55
received consulting / advisory honoraria from boehringer ingelheim, astrazeneca, omniseq, onxeo, the longevity labs, inzen, imvax, sotio, promont (LABEL_1) - Confidence: 0.60
##ory (LABEL_0) - Confidence: 0.50
, noxopharm, educom, and the luke heller tecpr2 foundation, and holds promontory stock option. 8. transl oncol. 2025 may 10 ; 57 : (LABEL_1) - Confidence: 0.62
102 (LABEL_0) - Confidence: 0.57
##407. (LABEL_1) - Confidence: 0.62
doi (LABEL_0) - Confidence: 0.51
: (LABEL_1) - Confidence: 0.75
10 (LABEL_0) - Confidence: 0.60
. (LABEL_1) - Confidence: 0.56
101 (LABEL_0) - Confidence: 0.54
##6 / j. tranon. 2025. (LABEL_1) - Confidence: 0.60
102 (LABEL_0) - Confidence: 0.59
##407. online ahead of print. molecular characterisation of the residual disease after neoadjuvant endoc (LABEL_1) - Confidence: 0.62
##rine (LABEL_0) - Confidence: 0.52
therapy (LABEL_1) - Confidence: 0.52
in (LABEL_0) - Confidence: 0.52
er + / her2 - (LABEL_1) - Confidence: 0.58
breast (LABEL_0) - Confidence: 0.54
cancer uncovers biomarkers of tumour response. lopez - velazco ji ( 1 ), manzano s ( 1 ), el (LABEL_1) - Confidence: 0.59
##or (LABEL_0) - Confidence: 0.51
##riaga k ( 2 ), otano m ( 3 ), lahuerta a ( 3 ), alvar (LABEL_1) - Confidence: 0.57
##ez (LABEL_0) - Confidence: 0.59
l ( (LABEL_1) - Confidence: 0.56
4 (LABEL_0) - Confidence: 0.53
), etxabe i ( (LABEL_1) - Confidence: 0.60
5 (LABEL_0) - Confidence: 0.55
), huarte m ( (LABEL_1) - Confidence: 0.57
5 (LABEL_0) - Confidence: 0.55
), buch e ( (LABEL_1) - Confidence: 0.57
6 (LABEL_0) - Confidence: 0.53
), gimenez j ( 7 ), q (LABEL_1) - Confidence: 0.58
##ui (LABEL_0) - Confidence: 0.60
##roga v ( 8 ), fernandez m ( (LABEL_1) - Confidence: 0.58
9 (LABEL_0) - Confidence: 0.56
), aragon s ( (LABEL_1) - Confidence: 0.57
10 (LABEL_0) - Confidence: 0.61
), par (LABEL_1) - Confidence: 0.57
##e (LABEL_0) - Confidence: 0.52
l ( (LABEL_1) - Confidence: 0.55
11 (LABEL_0) - Confidence: 0.51
), prat a ( 11 ), alvar (LABEL_1) - Confidence: 0.58
##ez (LABEL_0) - Confidence: 0.53
- lopez i ( 3 ), caffarel mm ( (LABEL_1) - Confidence: 0.59
12 (LABEL_0) - Confidence: 0.51
), urruticoechea a ( (LABEL_1) - Confidence: 0.62
13 (LABEL_0) - Confidence: 0.51
). author information : (LABEL_1) - Confidence: 0.62
( (LABEL_0) - Confidence: 0.51
1 ) biogipuzkoa ( previously known as biodonostia ) health (LABEL_1) - Confidence: 0.61
research (LABEL_0) - Confidence: 0.58
ins (LABEL_1) - Confidence: 0.60

----------------------------------------

--- SUMMARY for Chunk 23 ---
 Gipuzkoa Pathology Unit, OSI Donostialdea - Onkologikoa, San SebastiÃ¡n, Spain, is a pathology unit .

--- ENTITIES for Chunk 23 ---
t (LABEL_0) - Confidence: 0.50
##it (LABEL_1) - Confidence: 0.50
##ute (LABEL_0) - Confidence: 0.52
, san (LABEL_1) - Confidence: 0.60
se (LABEL_0) - Confidence: 0.52
##bastian, spa (LABEL_1) - Confidence: 0.57
##in (LABEL_0) - Confidence: 0.51
. ( 2 ) gipuzkoa pathology unit, osi donost (LABEL_1) - Confidence: 0.63
##ialdea (LABEL_0) - Confidence: 0.56
- onkologikoa, san (LABEL_1) - Confidence: 0.60
se (LABEL_0) - Confidence: 0.52
##bastian, spa (LABEL_1) - Confidence: 0.57
##in (LABEL_0) - Confidence: 0.52
. (LABEL_1) - Confidence: 0.62
( 3 ) bio (LABEL_0) - Confidence: 0.53
##gipuzkoa ( previously known as (LABEL_1) - Confidence: 0.57
bio (LABEL_0) - Confidence: 0.61
##donost (LABEL_1) - Confidence: 0.54
##ia (LABEL_0) - Confidence: 0.51
) health (LABEL_1) - Confidence: 0.64
research institute (LABEL_0) - Confidence: 0.57
, (LABEL_1) - Confidence: 0.69
sa (LABEL_0) - Confidence: 0.59
##n (LABEL_1) - Confidence: 0.52
sebastian (LABEL_0) - Confidence: 0.56
, (LABEL_1) - Confidence: 0.70
spain (LABEL_0) - Confidence: 0.57
; gip (LABEL_1) - Confidence: 0.66
##uz (LABEL_0) - Confidence: 0.50
##koa cancer unit / osi donost (LABEL_1) - Confidence: 0.60
##ialdea (LABEL_0) - Confidence: 0.62
- on (LABEL_1) - Confidence: 0.60
##kolog (LABEL_0) - Confidence: 0.51
##ikoa, (LABEL_1) - Confidence: 0.61
sa (LABEL_0) - Confidence: 0.53
##n (LABEL_1) - Confidence: 0.56
sebas (LABEL_0) - Confidence: 0.54
##tian, (LABEL_1) - Confidence: 0.62
spain (LABEL_0) - Confidence: 0.52
. (LABEL_1) - Confidence: 0.60
( 4 ) bio (LABEL_0) - Confidence: 0.56
##gipuzkoa ( previously known as (LABEL_1) - Confidence: 0.58
bio (LABEL_0) - Confidence: 0.60
##donost (LABEL_1) - Confidence: 0.54
##ia (LABEL_0) - Confidence: 0.52
) health (LABEL_1) - Confidence: 0.65
research institute (LABEL_0) - Confidence: 0.56
, (LABEL_1) - Confidence: 0.70
sa (LABEL_0) - Confidence: 0.55
##n (LABEL_1) - Confidence: 0.54
sebastian (LABEL_0) - Confidence: 0.54
, (LABEL_1) - Confidence: 0.72
spain (LABEL_0) - Confidence: 0.55
; gynecology and general surgery departments - breast unit, onkologikoa, (LABEL_1) - Confidence: 0.64
sa (LABEL_0) - Confidence: 0.53
##n (LABEL_1) - Confidence: 0.56
sebastian (LABEL_0) - Confidence: 0.54
, (LABEL_1) - Confidence: 0.71
spain (LABEL_0) - Confidence: 0.54
. (LABEL_1) - Confidence: 0.61
( 5 (LABEL_0) - Confidence: 0.59
) gynecology and general surgery departments - breast unit, on (LABEL_1) - Confidence: 0.61
##kolog (LABEL_0) - Confidence: 0.53
##ikoa, (LABEL_1) - Confidence: 0.60
sa (LABEL_0) - Confidence: 0.57
##n (LABEL_1) - Confidence: 0.53
sebastian (LABEL_0) - Confidence: 0.57
, (LABEL_1) - Confidence: 0.68
spain (LABEL_0) - Confidence: 0.58
. (LABEL_1) - Confidence: 0.59
( 6 (LABEL_0) - Confidence: 0.58
) hospital clinico univers (LABEL_1) - Confidence: 0.56
##ita (LABEL_0) - Confidence: 0.60
##rio de v (LABEL_1) - Confidence: 0.52
##ale (LABEL_0) - Confidence: 0.58
##ncia, (LABEL_1) - Confidence: 0.61
spain (LABEL_0) - Confidence: 0.57
. (LABEL_1) - Confidence: 0.61
( (LABEL_0) - Confidence: 0.52
7 ) valencia oncology (LABEL_1) - Confidence: 0.57
institute (LABEL_0) - Confidence: 0.52
, v (LABEL_1) - Confidence: 0.59
##ale (LABEL_0) - Confidence: 0.54
##ncia, (LABEL_1) - Confidence: 0.61
spain (LABEL_0) - Confidence: 0.55
. ( 8 ) catalan institute of oncology, badalona, spa (LABEL_1) - Confidence: 0.61
##in (LABEL_0) - Confidence: 0.52
. (LABEL_1) - Confidence: 0.63
( 9 ) bio (LABEL_0) - Confidence: 0.53
##gi (LABEL_1) - Confidence: 0.55
##pu (LABEL_0) - Confidence: 0.51
##z (LABEL_1) - Confidence: 0.53
##ko (LABEL_0) - Confidence: 0.52
##a ( previously known as (LABEL_1) - Confidence: 0.59
bio (LABEL_0) - Confidence: 0.61
##donost (LABEL_1) - Confidence: 0.54
##ia (LABEL_0) - Confidence: 0.54
) health (LABEL_1) - Confidence: 0.64
research institute (LABEL_0) - Confidence: 0.56
, (LABEL_1) - Confidence: 0.68
sa (LABEL_0) - Confidence: 0.55
##n (LABEL_1) - Confidence: 0.53
sebastian (LABEL_0) - Confidence: 0.58
, (LABEL_1) - Confidence: 0.70
spain (LABEL_0) - Confidence: 0.57
; gynecology department - breast unit, osi donost (LABEL_1) - Confidence: 0.62
##ialdea (LABEL_0) - Confidence: 0.63
, (LABEL_1) - Confidence: 0.67
sa (LABEL_0) - Confidence: 0.56
##n (LABEL_1) - Confidence: 0.53
sebastian (LABEL_0) - Confidence: 0.58
, (LABEL_1) - Confidence: 0.68
spain (LABEL_0) - Confidence: 0.56
. (LABEL_1) - Confidence: 0.59
( 10 (LABEL_0) - Confidence: 0.59
) hospital oct (LABEL_1) - Confidence: 0.58
##obe (LABEL_0) - Confidence: 0.53
##r 12, madrid, (LABEL_1) - Confidence: 0.60
spain (LABEL_0) - Confidence: 0.55
. ( (LABEL_1) - Confidence: 0.55
11 (LABEL_0) - Confidence: 0.51
) hospital clinic, barcelona - id (LABEL_1) - Confidence: 0.57
##iba (LABEL_0) - Confidence: 0.51
##ps, barcelon (LABEL_1) - Confidence: 0.59

----------------------------------------

--- SUMMARY for Chunk 24 ---
 Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive breast cancer (ER+/HER2-negative breast cancer) allows real-time evaluation of Â treatment sensitivity by monitoring tumour response and offers the opportunity  of personalised therapy .

--- ENTITIES for Chunk 24 ---
a, (LABEL_1) - Confidence: 0.59
spain (LABEL_0) - Confidence: 0.51
. ( (LABEL_1) - Confidence: 0.61
12 (LABEL_0) - Confidence: 0.53
) (LABEL_1) - Confidence: 0.53
bio (LABEL_0) - Confidence: 0.50
##gipuzkoa ( previously known as (LABEL_1) - Confidence: 0.59
bio (LABEL_0) - Confidence: 0.58
##donostia ) health (LABEL_1) - Confidence: 0.59
research institute (LABEL_0) - Confidence: 0.58
, (LABEL_1) - Confidence: 0.72
sa (LABEL_0) - Confidence: 0.52
##n sebastian, (LABEL_1) - Confidence: 0.59
spain (LABEL_0) - Confidence: 0.53
; ikerbasque, basque foundation for science, bilbao, spain. electronic address : maria. munozcaffarel @ (LABEL_1) - Confidence: 0.61
bio (LABEL_0) - Confidence: 0.52
- g (LABEL_1) - Confidence: 0.59
##ip (LABEL_0) - Confidence: 0.50
##uzkoa. eus. ( (LABEL_1) - Confidence: 0.57
13 (LABEL_0) - Confidence: 0.61
) (LABEL_1) - Confidence: 0.52
bio (LABEL_0) - Confidence: 0.56
##gi (LABEL_1) - Confidence: 0.55
##pu (LABEL_0) - Confidence: 0.51
##zkoa ( previously known as (LABEL_1) - Confidence: 0.57
bio (LABEL_0) - Confidence: 0.62
##donost (LABEL_1) - Confidence: 0.56
##ia (LABEL_0) - Confidence: 0.52
) health (LABEL_1) - Confidence: 0.61
research institute (LABEL_0) - Confidence: 0.61
, (LABEL_1) - Confidence: 0.69
sa (LABEL_0) - Confidence: 0.59
##n (LABEL_1) - Confidence: 0.55
sebastian (LABEL_0) - Confidence: 0.53
, (LABEL_1) - Confidence: 0.72
spain (LABEL_0) - Confidence: 0.60
; gipuzkoa cancer unit / osi donostialdea - onkologikoa, (LABEL_1) - Confidence: 0.64
sa (LABEL_0) - Confidence: 0.51
##n (LABEL_1) - Confidence: 0.60
sebas (LABEL_0) - Confidence: 0.51
##tian, (LABEL_1) - Confidence: 0.63
spain (LABEL_0) - Confidence: 0.55
. electronic address : aurruticoechea @ onkologikoa. org. (LABEL_1) - Confidence: 0.62
background (LABEL_0) - Confidence: 0.57
: neoadjuvant endocrine therapy ( net ) (LABEL_1) - Confidence: 0.60
in (LABEL_0) - Confidence: 0.53
oestrogen receptor - positive / (LABEL_1) - Confidence: 0.59
her (LABEL_0) - Confidence: 0.51
##2 - (LABEL_1) - Confidence: 0.55
negative breast (LABEL_0) - Confidence: 0.52
cancer ( er + / her2 - (LABEL_1) - Confidence: 0.59
b (LABEL_0) - Confidence: 0.51
##c ) allows (LABEL_1) - Confidence: 0.56
real (LABEL_0) - Confidence: 0.52
- (LABEL_1) - Confidence: 0.59
time (LABEL_0) - Confidence: 0.57
evaluation of treatment sensitivity by monitoring (LABEL_1) - Confidence: 0.55
t (LABEL_0) - Confidence: 0.52
##umour response (LABEL_1) - Confidence: 0.53
and (LABEL_0) - Confidence: 0.50
offers the opportunity of (LABEL_1) - Confidence: 0.58
personal (LABEL_0) - Confidence: 0.52
##ised therapy. (LABEL_1) - Confidence: 0.57
however (LABEL_0) - Confidence: 0.52
, the lack of reprod (LABEL_1) - Confidence: 0.57
##uc (LABEL_0) - Confidence: 0.55
##ible biomarkers to assess response and long - term pro (LABEL_1) - Confidence: 0.57
##gnosis (LABEL_0) - Confidence: 0.52
after net (LABEL_1) - Confidence: 0.59
is (LABEL_0) - Confidence: 0.55
a significant (LABEL_1) - Confidence: 0.55
barrier (LABEL_0) - Confidence: 0.55
to increase its indications. methods : in this study we searched for (LABEL_1) - Confidence: 0.60
clinical (LABEL_0) - Confidence: 0.51
##ly relevant molecular reporters of response to net in a multi (LABEL_1) - Confidence: 0.60
##cent (LABEL_0) - Confidence: 0.51
##re population of (LABEL_1) - Confidence: 0.61

----------------------------------------

--- SUMMARY for Chunk 25 ---
 Tumours changing from luminal A to normal-like subtype after NET presented better radiological and pathological responses . Patients with highest response to NET showed the largest decrease in PAM50-derived  risk of recurrence (ROR) following NET .

--- ENTITIES for Chunk 25 ---
er + / (LABEL_1) - Confidence: 0.57
her (LABEL_0) - Confidence: 0.54
##2 - (LABEL_1) - Confidence: 0.56
b (LABEL_0) - Confidence: 0.53
##c patients ( n = 87 ) by using : pam50 gene expression panel and immunohistochemical evaluation of key proteins involved in tumorige (LABEL_1) - Confidence: 0.61
##nes (LABEL_0) - Confidence: 0.52
##is. (LABEL_1) - Confidence: 0.58
results (LABEL_0) - Confidence: 0.51
: our pam50 analyses show that tumours changing from l (LABEL_1) - Confidence: 0.62
##umi (LABEL_0) - Confidence: 0.56
##nal a to normal - like (LABEL_1) - Confidence: 0.56
subtype after (LABEL_0) - Confidence: 0.52
net (LABEL_1) - Confidence: 0.59
presented (LABEL_0) - Confidence: 0.52
better (LABEL_1) - Confidence: 0.52
radio (LABEL_0) - Confidence: 0.51
##logical and pathological tumour responses, a significant larger decrease (LABEL_1) - Confidence: 0.57
in ki (LABEL_0) - Confidence: 0.55
##67 at surgery, lower preoperative endocrine prognostic (LABEL_1) - Confidence: 0.57
index (LABEL_0) - Confidence: 0.51
score ( pep (LABEL_1) - Confidence: 0.55
##i (LABEL_0) - Confidence: 0.52
) and lower (LABEL_1) - Confidence: 0.55
t (LABEL_0) - Confidence: 0.51
##umour cellularity size ( tcs ) than those with persistent luminal a status. patients with the highest response to net showed the largest decrease (LABEL_1) - Confidence: 0.61
in (LABEL_0) - Confidence: 0.50
pam50 - derived risk of (LABEL_1) - Confidence: 0.61
re (LABEL_0) - Confidence: 0.54
##cu (LABEL_1) - Confidence: 0.54
##rrence (LABEL_0) - Confidence: 0.52
( (LABEL_1) - Confidence: 0.64
r (LABEL_0) - Confidence: 0.53
##or ) following net. in addition, the (LABEL_1) - Confidence: 0.60
percentage (LABEL_0) - Confidence: 0.53
of (LABEL_1) - Confidence: 0.56
p53 (LABEL_0) - Confidence: 0.52
positive (LABEL_1) - Confidence: 0.53
cells (LABEL_0) - Confidence: 0.51
was associated with decreased response to net. conclusions : our findings highlight the (LABEL_1) - Confidence: 0.58
change (LABEL_0) - Confidence: 0.52
of intrinsic sub (LABEL_1) - Confidence: 0.57
##type (LABEL_0) - Confidence: 0.50
from l (LABEL_1) - Confidence: 0.58
##umi (LABEL_0) - Confidence: 0.58
##nal a to normal - like (LABEL_1) - Confidence: 0.55
after (LABEL_0) - Confidence: 0.55
net as a putative (LABEL_1) - Confidence: 0.57
biomark (LABEL_0) - Confidence: 0.52
##er characterising the patient population that obtains the highest benefit from net. our study also suggests that changes in p (LABEL_1) - Confidence: 0.59

----------------------------------------

--- SUMMARY for Chunk 26 ---
 This study uncovers potential biomarkers of response to NET and prognosis, which should be validated in independent cohorts . AM50-derived ROR score and p53 evaluation could also help to identify patients .

--- ENTITIES for Chunk 26 ---
am50 - derived ror score and p53 evaluation could also (LABEL_1) - Confidence: 0.59
help (LABEL_0) - Confidence: 0.50
to identify those patients. thus, this study uncovers potential bio (LABEL_1) - Confidence: 0.59
##mark (LABEL_0) - Confidence: 0.52
##ers of response to net and pro (LABEL_1) - Confidence: 0.59
##gno (LABEL_0) - Confidence: 0.53
##sis, which (LABEL_1) - Confidence: 0.58
should (LABEL_0) - Confidence: 0.52
be validated in independent cohorts, (LABEL_1) - Confidence: 0.59
helping to the (LABEL_0) - Confidence: 0.54
implementation of net (LABEL_1) - Confidence: 0.56
in (LABEL_0) - Confidence: 0.54
the clinical practice. copyright Â© 2025. published by elsevier inc. (LABEL_1) - Confidence: 0.58
doi (LABEL_0) - Confidence: 0.63
: (LABEL_1) - Confidence: 0.66
10. 101 (LABEL_0) - Confidence: 0.61
##6 / (LABEL_1) - Confidence: 0.54
j (LABEL_0) - Confidence: 0.53
. (LABEL_1) - Confidence: 0.56
t (LABEL_0) - Confidence: 0.50
##ranon. (LABEL_1) - Confidence: 0.58
202 (LABEL_0) - Confidence: 0.50
##5. (LABEL_1) - Confidence: 0.58
102 (LABEL_0) - Confidence: 0.56
##407 pmid : 40349505 conflict of interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 9. c (LABEL_1) - Confidence: 0.65
##lin (LABEL_0) - Confidence: 0.59
breast cancer. 2025 apr 15 : s1526 - 8209 ( 25 ) 00102 - 8. (LABEL_1) - Confidence: 0.64
doi (LABEL_0) - Confidence: 0.64
: (LABEL_1) - Confidence: 0.68
10. 101 (LABEL_0) - Confidence: 0.63
##6 / (LABEL_1) - Confidence: 0.53
j (LABEL_0) - Confidence: 0.56
. clbc. 202 (LABEL_1) - Confidence: 0.55
##5 (LABEL_0) - Confidence: 0.52
. 04. 011. online ahead of print. (LABEL_1) - Confidence: 0.60
cost - effectiveness (LABEL_0) - Confidence: 0.55
of prosigna for adjuvant treatment decisions (LABEL_1) - Confidence: 0.58
in (LABEL_0) - Confidence: 0.56
early breast cancer : healthcare sector and societal perspectives. asphaug l ( 1 ), akslen la ( 2 ), blix es ( 3 ), boge b ( 4 ), borgen ef ( 5 ), brekke mb ( 6 ), falk rs ( 7 ), geitvik ga ( 8 ), gilje b ( 9 ), gravdeha (LABEL_1) - Confidence: 0.60

----------------------------------------

--- SUMMARY for Chunk 27 ---
 Clinical Trials Unit, Oslo University Hospital, Oslo, Norway; Department of Oncology, University of North Norway, TromsÃ¸, Norway . Department of Clinical Medicine, UiT The Arctic University of Norway, . The author of the study is Professor L. ug B(10), Heie A(11), Janssen E(12), Kiserud CE(13), Kursetgjerde CE(14), LangerÃ¸d A(8), LÃ¸mo J(5), MannsÃ¥ker B(15), Mortensen E(16), Olsson P(17), Poroj

--- ENTITIES for Chunk 27 ---
ug (LABEL_1) - Confidence: 0.57
b (LABEL_0) - Confidence: 0.53
( (LABEL_1) - Confidence: 0.62
10 (LABEL_0) - Confidence: 0.51
), heie a ( 11 ), janssen e ( 12 ), kiserud ce ( 13 ), kursetgjerde t ( 14 ), langerÃ¸d a ( 8 ), lÃ¸mo j ( 5 ), mannsaker b ( 15 ), mortensen e ( 16 ), olsson p ( 17 ), porojnicu ac ( 18 ), raj sx ( 19 ), roe od ( 20 ), russnes heg ( 21 ), skjerven hk ( 22 ), songe - mÃ¸ller s ( 23 ), vestlid ma ( 24 ), ohnstad ho ( 25 ), naume b ( 26 ). author information : ( (LABEL_1) - Confidence: 0.62
1 (LABEL_0) - Confidence: 0.55
) (LABEL_1) - Confidence: 0.55
clinical trials (LABEL_0) - Confidence: 0.53
unit, oslo university hospital, oslo, nor (LABEL_1) - Confidence: 0.57
##way (LABEL_0) - Confidence: 0.56
; (LABEL_1) - Confidence: 0.73
department (LABEL_0) - Confidence: 0.52
of health management and health (LABEL_1) - Confidence: 0.59
economics (LABEL_0) - Confidence: 0.55
, (LABEL_1) - Confidence: 0.67
institute (LABEL_0) - Confidence: 0.60
of health (LABEL_1) - Confidence: 0.62
and (LABEL_0) - Confidence: 0.53
society, university of oslo, oslo, norway. electronic address : larasp @ ous - hf. no. ( 2 ) centre for cancer biomarkers ccbio, department of clinical medicine, section for pathology, university of bergen, (LABEL_1) - Confidence: 0.62
be (LABEL_0) - Confidence: 0.51
##rgen, nor (LABEL_1) - Confidence: 0.60
##way (LABEL_0) - Confidence: 0.52
; department of pathology haukeland university hospital, (LABEL_1) - Confidence: 0.64
be (LABEL_0) - Confidence: 0.51
##rgen, norway. (LABEL_1) - Confidence: 0.59
( 3 (LABEL_0) - Confidence: 0.54
) department of oncology, university of north norway, (LABEL_1) - Confidence: 0.61
t (LABEL_0) - Confidence: 0.50
##romsÃ¸, norway ; (LABEL_1) - Confidence: 0.61
department (LABEL_0) - Confidence: 0.55
of clinical medicine, uit the arctic university of norway, tromsÃ¸, norway. (LABEL_1) - Confidence: 0.61
( 4 (LABEL_0) - Confidence: 0.59
) (LABEL_1) - Confidence: 0.53
department (LABEL_0) - Confidence: 0.50
of oncology, hospital of southern norway, kristiansand, norway. ( (LABEL_1) - Confidence: 0.62
5 (LABEL_0) - Confidence: 0.60
) department of p (LABEL_1) - Confidence: 0.64

----------------------------------------

--- SUMMARY for Chunk 28 ---
 Department of Pathology, Department of Haematology and Oncology, Stavanger University Hospital, Norway; Department of Breast Surgery, Akershus University Hospital . Department of Cancer Genetics, Institute for Cancer Research, Oslo University  Â  Â  Â  Â  Â  Â  Â  Â Hospital, Oslo, Norway. Department of Clinical Research,  Â  Â  Â  Â  Â  Â  Â  Â  University of Norway, University of Oslo University, Norway, and Department of Chemistry, Bioscience and Environmental Engineering . Department for Cancer Treatment, Oslo  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â University Hospital, Oslo Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â Â UniversityÂ University, Norway . University of Queensland and Griffith University, Southport, Australia. University of Southport

--- ENTITIES for Chunk 28 ---
athology, division of laboratory medicine, oslo university hospital, oslo, nor (LABEL_1) - Confidence: 0.62
##way (LABEL_0) - Confidence: 0.50
. ( (LABEL_1) - Confidence: 0.61
6 (LABEL_0) - Confidence: 0.55
) department of pathology, st olavs hospital, trondheim, norway. ( 7 ) oslo centre for biostatistics and epidemiology, oslo university hospital, oslo, nor (LABEL_1) - Confidence: 0.61
##way (LABEL_0) - Confidence: 0.54
. ( (LABEL_1) - Confidence: 0.57
8 (LABEL_0) - Confidence: 0.52
) (LABEL_1) - Confidence: 0.52
department (LABEL_0) - Confidence: 0.51
of cancer genetics, (LABEL_1) - Confidence: 0.62
institute (LABEL_0) - Confidence: 0.56
for cancer (LABEL_1) - Confidence: 0.56
research (LABEL_0) - Confidence: 0.53
, oslo university hospital, oslo, nor (LABEL_1) - Confidence: 0.57
##way (LABEL_0) - Confidence: 0.54
. ( (LABEL_1) - Confidence: 0.58
9 (LABEL_0) - Confidence: 0.50
) department of (LABEL_1) - Confidence: 0.57
ha (LABEL_0) - Confidence: 0.51
##ematology and oncology, stavanger university hospital, stavanger, norway. ( (LABEL_1) - Confidence: 0.60
10 (LABEL_0) - Confidence: 0.57
) department of breast surgery, akershus university hospital, lÃ¸renskog, norway. ( (LABEL_1) - Confidence: 0.64
11 (LABEL_0) - Confidence: 0.52
) (LABEL_1) - Confidence: 0.51
department (LABEL_0) - Confidence: 0.50
of breast surgery, haukeland university hospital, bergen, norway. ( (LABEL_1) - Confidence: 0.61
12 ) department (LABEL_0) - Confidence: 0.53
of pathology, s (LABEL_1) - Confidence: 0.62
##ta (LABEL_0) - Confidence: 0.55
##vanger university hospital, s (LABEL_1) - Confidence: 0.56
##ta (LABEL_0) - Confidence: 0.55
##vanger, (LABEL_1) - Confidence: 0.58
norway (LABEL_0) - Confidence: 0.55
; (LABEL_1) - Confidence: 0.73
department (LABEL_0) - Confidence: 0.52
of chemistry, bioscience and environmental engineering, s (LABEL_1) - Confidence: 0.59
##ta (LABEL_0) - Confidence: 0.53
##vanger university, s (LABEL_1) - Confidence: 0.59
##ta (LABEL_0) - Confidence: 0.53
##vanger, (LABEL_1) - Confidence: 0.60
norway (LABEL_0) - Confidence: 0.53
; menzies health institute queensland and griffith university, southport, austra (LABEL_1) - Confidence: 0.64
##lia (LABEL_0) - Confidence: 0.52
. ( (LABEL_1) - Confidence: 0.59
13 (LABEL_0) - Confidence: 0.56
) national advisory unit for late effects after cancer treatment, oslo university hospital, oslo, nor (LABEL_1) - Confidence: 0.58
##way (LABEL_0) - Confidence: 0.54
. ( 14 ) departm (LABEL_1) - Confidence: 0.62

----------------------------------------

--- SUMMARY for Chunk 29 ---
 Department of Oncology, MÃ¸re og Romsdal Hospital Trust, Ãlesund, Norway . Department of Pathology, University of North Norway, TromsÃ¸, Norway. Department of Breast Surgery, Innlandet Hospital Trust . Department  of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Department of Clinical Medicine, Division of Laboratory Medicine, Oslo .

--- ENTITIES for Chunk 29 ---
ent of oncology, mÃ¸re og romsdal hospital trust, alesund, norway. ( 15 ) department of oncology, nordland hospital, bodÃ¸, norway. ( 16 ) department of pathology, university of north norway, tromsÃ¸, norway. ( 17 ) department of breast surgery, innlandet hospital (LABEL_1) - Confidence: 0.63
trust (LABEL_0) - Confidence: 0.56
, hamar, norway. ( 18 ) department of oncology, vestre viken hospital (LABEL_1) - Confidence: 0.59
trust (LABEL_0) - Confidence: 0.57
, drammen, norway. ( 19 ) department of oncology, st olavs hospital, t (LABEL_1) - Confidence: 0.62
##ron (LABEL_0) - Confidence: 0.52
##dheim, norway. ( 20 ) department of oncology, levanger hospital, levanger, norway. ( 21 ) (LABEL_1) - Confidence: 0.60
institute (LABEL_0) - Confidence: 0.50
of clinical medicine, (LABEL_1) - Confidence: 0.65
university (LABEL_0) - Confidence: 0.51
of oslo, oslo, nor (LABEL_1) - Confidence: 0.63
##way (LABEL_0) - Confidence: 0.52
; (LABEL_1) - Confidence: 0.73
department (LABEL_0) - Confidence: 0.51
of pathology, division of laboratory medicine, oslo university hospital, oslo, nor (LABEL_1) - Confidence: 0.60
##way (LABEL_0) - Confidence: 0.54
; (LABEL_1) - Confidence: 0.74
department (LABEL_0) - Confidence: 0.52
of cancer genetics, (LABEL_1) - Confidence: 0.64
institute (LABEL_0) - Confidence: 0.51
for cancer research, oslo university hospital, oslo, nor (LABEL_1) - Confidence: 0.59
##way (LABEL_0) - Confidence: 0.50
. ( 22 ) department of breast surgery, vestre viken hospital (LABEL_1) - Confidence: 0.57
trust (LABEL_0) - Confidence: 0.56
, drammen, norway. ( 23 ) department of oncology, Ã¸stfold hospital (LABEL_1) - Confidence: 0.63
trust (LABEL_0) - Confidence: 0.51
, kalnes, norway. ( 24 ) department of breast surgery, telemark hospital (LABEL_1) - Confidence: 0.60
trust (LABEL_0) - Confidence: 0.55
, skien, norway. ( (LABEL_1) - Confidence: 0.59
25 (LABEL_0) - Confidence: 0.52
) department of oncolog (LABEL_1) - Confidence: 0.59

----------------------------------------

--- SUMMARY for Chunk 30 ---
 Gene expression profiling tests such as the Prosigna-assay are used to aid adjuvant treatment decisions in hormone receptor positive (HR+) HER2+ HER2-negative (HER2-) early breast cancer (EBC)

--- ENTITIES for Chunk 30 ---
y, division of cancer medicine, oslo university hospital, oslo, norway. ( 26 ) department of oncology, (LABEL_1) - Confidence: 0.60
division (LABEL_0) - Confidence: 0.50
of cancer medicine, oslo university hospital, oslo, norway ; (LABEL_1) - Confidence: 0.63
institute (LABEL_0) - Confidence: 0.54
of clinical medicine, university of oslo, oslo, norway. background : gene (LABEL_1) - Confidence: 0.61
expression (LABEL_0) - Confidence: 0.52
profiling tests such as the prosigna - assay are (LABEL_1) - Confidence: 0.59
used (LABEL_0) - Confidence: 0.50
to aid adjuvant treatment (LABEL_1) - Confidence: 0.58
decisions in (LABEL_0) - Confidence: 0.55
hormone receptor positive ( hr + ) her2 negative ( her2 - ) early breast cancer ( ebc ). in this evaluation, the (LABEL_1) - Confidence: 0.57
cost - (LABEL_0) - Confidence: 0.55
effectiveness of prosigna against immunohistochemical ( ihc ) markers including (LABEL_1) - Confidence: 0.58
ki - 67 (LABEL_0) - Confidence: 0.54
, was evaluated from the norwegian healthcare - (LABEL_1) - Confidence: 0.58
and (LABEL_0) - Confidence: 0.58
societal perspective (LABEL_1) - Confidence: 0.56
. materials (LABEL_0) - Confidence: 0.53
and (LABEL_1) - Confidence: 0.63
methods (LABEL_0) - Confidence: 0.50
: the (LABEL_1) - Confidence: 0.61
treatment (LABEL_0) - Confidence: 0.56
decision (LABEL_1) - Confidence: 0.51
impact of (LABEL_0) - Confidence: 0.52
prosigna was tested (LABEL_1) - Confidence: 0.56
in (LABEL_0) - Confidence: 0.54
the (LABEL_1) - Confidence: 0.52
prospective (LABEL_0) - Confidence: 0.55
, (LABEL_1) - Confidence: 0.54
observation (LABEL_0) - Confidence: 0.51
##al (LABEL_1) - Confidence: 0.56
emit - 1 trial (LABEL_0) - Confidence: 0.52
. using individual data collected the first 12 months (LABEL_1) - Confidence: 0.56
post (LABEL_0) - Confidence: 0.55
- (LABEL_1) - Confidence: 0.53
surgery (LABEL_0) - Confidence: 0.51
, a (LABEL_1) - Confidence: 0.60
decision (LABEL_0) - Confidence: 0.53
model was (LABEL_1) - Confidence: 0.57
built (LABEL_0) - Confidence: 0.53
to project the economic consequences of using the prosigna compared to ihc - markers for the adjuvant treatment decisions. health (LABEL_1) - Confidence: 0.59
benefits (LABEL_0) - Confidence: 0.54
were measured (LABEL_1) - Confidence: 0.58

----------------------------------------

--- SUMMARY for Chunk 31 ---
 Of 2,178 HR+/HER2- pN0 EBC patients in the EMIT-1 trial, 1,985 had health economic data and 1,850 had complete income and welfare benefit records . Prosigna-assay was cost-effective in both the healthcare and societal  perspectives .

--- ENTITIES for Chunk 31 ---
by (LABEL_1) - Confidence: 0.56
cost (LABEL_0) - Confidence: 0.55
per quality - adjusted life - (LABEL_1) - Confidence: 0.55
years (LABEL_0) - Confidence: 0.62
( qalys ) and data on income and welfare (LABEL_1) - Confidence: 0.58
benefit (LABEL_0) - Confidence: 0.52
was obtained from statistics norway. (LABEL_1) - Confidence: 0.61
results (LABEL_0) - Confidence: 0.56
: of 2, 178 hr + / her2 - pn0 ebc patients (LABEL_1) - Confidence: 0.61
in (LABEL_0) - Confidence: 0.51
the emit (LABEL_1) - Confidence: 0.53
- (LABEL_0) - Confidence: 0.52
1 trial, 1, 985 had available health economic data and 1, 850 had complete income and welfare (LABEL_1) - Confidence: 0.63
benefit (LABEL_0) - Confidence: 0.53
records. including all pn0 patients (LABEL_1) - Confidence: 0.60
in the (LABEL_0) - Confidence: 0.51
prosigna - test strategy, the test (LABEL_1) - Confidence: 0.57
was (LABEL_0) - Confidence: 0.54
above (LABEL_1) - Confidence: 0.52
the cost - (LABEL_0) - Confidence: 0.59
effective (LABEL_1) - Confidence: 0.53
threshold (LABEL_0) - Confidence: 0.59
( (LABEL_1) - Confidence: 0.50
â¬ (LABEL_0) - Confidence: 0.69
##26, 000 ; (LABEL_1) - Confidence: 0.66
incre (LABEL_0) - Confidence: 0.58
##mental (LABEL_1) - Confidence: 0.67
cost (LABEL_0) - Confidence: 0.63
- per q (LABEL_1) - Confidence: 0.55
##aly (LABEL_0) - Confidence: 0.52
gained ( (LABEL_1) - Confidence: 0.58
ice (LABEL_0) - Confidence: 0.51
##r ) (LABEL_1) - Confidence: 0.58
â¬ (LABEL_0) - Confidence: 0.62
##255, 622 ) in a healthcare (LABEL_1) - Confidence: 0.60
sector (LABEL_0) - Confidence: 0.51
perspective. incorporating also productivity costs, prosigna (LABEL_1) - Confidence: 0.60
was cost - saving (LABEL_0) - Confidence: 0.58
( icer (LABEL_1) - Confidence: 0.54
â¬ (LABEL_0) - Confidence: 0.54
- 435, 677 ) (LABEL_1) - Confidence: 0.61
. (LABEL_0) - Confidence: 0.54
restricting prosigna - testing to patients assessed as clear / uncertain (LABEL_1) - Confidence: 0.57
chemotherapy (LABEL_0) - Confidence: 0.53
candidates, the strategy (LABEL_1) - Confidence: 0.58
was cost - effective (LABEL_0) - Confidence: 0.61
in both the healthcare (LABEL_1) - Confidence: 0.57
and (LABEL_0) - Confidence: 0.53
societal perspective ( (LABEL_1) - Confidence: 0.59
ice (LABEL_0) - Confidence: 0.54
##r (LABEL_1) - Confidence: 0.52
â¬ (LABEL_0) - Confidence: 0.61
##8884 and (LABEL_1) - Confidence: 0.62
â¬ (LABEL_0) - Confidence: 0.60
- 620170, (LABEL_1) - Confidence: 0.59
respectively (LABEL_0) - Confidence: 0.59
) (LABEL_1) - Confidence: 0.62
. conclusions (LABEL_0) - Confidence: 0.57
: using the prosigna - assay for all hr + / her2 - pn0 ebc patients (LABEL_1) - Confidence: 0.60
was (LABEL_0) - Confidence: 0.55
not (LABEL_1) - Confidence: 0.50
cost - effective (LABEL_0) - Confidence: 0.58
from a healthcare perspective, but from the societal perspective (LABEL_1) - Confidence: 0.59
it was cost - saving (LABEL_0) - Confidence: 0.57
. selecting patient (LABEL_1) - Confidence: 0.54

----------------------------------------

--- SUMMARY for Chunk 32 ---
 The authors have declared no conflicts of interest . The study was conducted at Imam Khomeini International University, Qazvin, Iran . The authors' findings are published ahead of print .

--- ENTITIES for Chunk 32 ---
s (LABEL_0) - Confidence: 0.51
who (LABEL_1) - Confidence: 0.58
are (LABEL_0) - Confidence: 0.50
clear / uncertain candidates for chemotherapy based on ihc - classification, prosigna (LABEL_1) - Confidence: 0.57
is cost - effective (LABEL_0) - Confidence: 0.55
from both (LABEL_1) - Confidence: 0.57
perspectives (LABEL_0) - Confidence: 0.51
. copyright Â© 2025 the authors. published by elsevier inc. all rights reserved. (LABEL_1) - Confidence: 0.66
doi (LABEL_0) - Confidence: 0.60
: (LABEL_1) - Confidence: 0.70
10 (LABEL_0) - Confidence: 0.65
. (LABEL_1) - Confidence: 0.52
101 (LABEL_0) - Confidence: 0.57
##6 / (LABEL_1) - Confidence: 0.56
j (LABEL_0) - Confidence: 0.54
. clbc. 2025. 04. 011 pmid : (LABEL_1) - Confidence: 0.58
40 (LABEL_0) - Confidence: 0.52
##348620 conflict of interest statement : disclosure the authors have declared no conflicts of interest. (LABEL_1) - Confidence: 0.65
10 (LABEL_0) - Confidence: 0.58
. (LABEL_1) - Confidence: 0.68
j (LABEL_0) - Confidence: 0.51
biotechnol. 2025 may 8 : s0168 - 1656 ( 25 ) 00108 - 7. (LABEL_1) - Confidence: 0.65
doi (LABEL_0) - Confidence: 0.58
: (LABEL_1) - Confidence: 0.76
10 (LABEL_0) - Confidence: 0.61
. (LABEL_1) - Confidence: 0.55
101 (LABEL_0) - Confidence: 0.60
##6 / (LABEL_1) - Confidence: 0.58
j (LABEL_0) - Confidence: 0.56
. (LABEL_1) - Confidence: 0.67
j (LABEL_0) - Confidence: 0.51
##biotec. 2025. 04. 022. online ahead of print. (LABEL_1) - Confidence: 0.61
inter (LABEL_0) - Confidence: 0.50
##fer (LABEL_1) - Confidence: 0.53
##on (LABEL_0) - Confidence: 0.50
gamma - induced hub genes and key pathways : a study based on biological network analysis and experimental validation. he (LABEL_1) - Confidence: 0.60
##ida (LABEL_0) - Confidence: 0.53
##ri - japelaghi r ( 1 ), valizadeh m ( 2 ), haddad r ( 3 ). author information : ( 1 ) department of biotechnology engineering, (LABEL_1) - Confidence: 0.60
faculty (LABEL_0) - Confidence: 0.58
of agriculture and natural (LABEL_1) - Confidence: 0.63
resources (LABEL_0) - Confidence: 0.52
, imam khomeini international university, qaz (LABEL_1) - Confidence: 0.60
##vin (LABEL_0) - Confidence: 0.50
, (LABEL_1) - Confidence: 0.69
i (LABEL_0) - Confidence: 0.62
##ran. electronic address : (LABEL_1) - Confidence: 0.67
re (LABEL_0) - Confidence: 0.51
##za. he (LABEL_1) - Confidence: 0.58
##idari (LABEL_0) - Confidence: 0.56
@ org. (LABEL_1) - Confidence: 0.58
i (LABEL_0) - Confidence: 0.50
##ki (LABEL_1) - Confidence: 0.57
##u (LABEL_0) - Confidence: 0.50
. ac. (LABEL_1) - Confidence: 0.59
i (LABEL_0) - Confidence: 0.54
##r. ( 2 ) department of plant breeding and biotechnology, (LABEL_1) - Confidence: 0.63
faculty (LABEL_0) - Confidence: 0.56
of agriculture, (LABEL_1) - Confidence: 0.65
university (LABEL_0) - Confidence: 0.53
of tabriz, (LABEL_1) - Confidence: 0.59
ta (LABEL_0) - Confidence: 0.51
##briz, (LABEL_1) - Confidence: 0.61
i (LABEL_0) - Confidence: 0.60
##ran. ( 3 ) department o (LABEL_1) - Confidence: 0.61

----------------------------------------

--- SUMMARY for Chunk 33 ---
 Some hub genes were up- or down-regulated in the breast cancer (BC) cell line after treatment  with IFN-Î³ . Several pathways including cytokine-cytokine receptor  interactions were detected that their activation leads to the ipientiproliferation, proapoptosis, and antiviral activities .

--- ENTITIES for Chunk 33 ---
f biotechnology engineering, (LABEL_1) - Confidence: 0.64
faculty (LABEL_0) - Confidence: 0.54
of agriculture and natural resources, imam khomeini international university, qazvin, (LABEL_1) - Confidence: 0.62
i (LABEL_0) - Confidence: 0.53
##ran. by performing a biological network analysis, we identified some hub (LABEL_1) - Confidence: 0.59
genes (LABEL_0) - Confidence: 0.54
, which (LABEL_1) - Confidence: 0.56
were up - (LABEL_0) - Confidence: 0.52
or (LABEL_1) - Confidence: 0.54
down - regulated (LABEL_0) - Confidence: 0.55
in the (LABEL_1) - Confidence: 0.57
breast (LABEL_0) - Confidence: 0.54
cancer ( bc ) cell line after treatment with (LABEL_1) - Confidence: 0.56
if (LABEL_0) - Confidence: 0.66
##n - Î³. moreover, several (LABEL_1) - Confidence: 0.56
pathways (LABEL_0) - Confidence: 0.54
including c (LABEL_1) - Confidence: 0.55
##ytoki (LABEL_0) - Confidence: 0.52
##ne - c (LABEL_1) - Confidence: 0.58
##ytoki (LABEL_0) - Confidence: 0.56
##ne receptor (LABEL_1) - Confidence: 0.60
interaction (LABEL_0) - Confidence: 0.51
, tnf signaling (LABEL_1) - Confidence: 0.60
pathway (LABEL_0) - Confidence: 0.52
, nod - like receptor signaling (LABEL_1) - Confidence: 0.62
pathway (LABEL_0) - Confidence: 0.53
, and nf - Îºb signaling pathway were (LABEL_1) - Confidence: 0.57
detected (LABEL_0) - Confidence: 0.50
that their activation leads to the antiprol (LABEL_1) - Confidence: 0.58
##ifer (LABEL_0) - Confidence: 0.56
##ation, pro (LABEL_1) - Confidence: 0.62
##ap (LABEL_0) - Confidence: 0.56
##optosis, and antiviral activities. to validate in silico results, the bioactivity of recombinant human (LABEL_1) - Confidence: 0.59
if (LABEL_0) - Confidence: 0.63
##n - Î³ ( hifn - Î³ ) produced in different hosts was analyzed by antiviral and anti (LABEL_1) - Confidence: 0.56
##can (LABEL_0) - Confidence: 0.58
##cer assays. the (LABEL_1) - Confidence: 0.61
anti (LABEL_0) - Confidence: 0.53
##viral role of the hifn - Î³ preparations was evaluated by (LABEL_1) - Confidence: 0.60
in (LABEL_0) - Confidence: 0.52
##hibition of vesicular stomatitis virus ( (LABEL_1) - Confidence: 0.62
vs (LABEL_0) - Confidence: 0.57
##v ) - mediated cytopathic effects on vero cells. a dose - dependent increase in cell (LABEL_1) - Confidence: 0.60
via (LABEL_0) - Confidence: 0.52
##bility was observed at different concentrations of recombinant (LABEL_1) - Confidence: 0.63

----------------------------------------

--- SUMMARY for Chunk 34 ---
 The highest level of inhibiting cell proliferation was detected at a concentration of hIFN-Î³ after 72h incubation . Anticancer and antiviral functions were confirmed via the expression analysis of hub genes cd74, cxcl10, il6, ipientand stat1 using RT-PCR .

--- ENTITIES for Chunk 34 ---
proteins. the maximum amount of the cell (LABEL_1) - Confidence: 0.64
via (LABEL_0) - Confidence: 0.52
##bility detected for the hifn - Î³ preparations was determined at a concentration of 32. 00pg / ml. to analyze the cyt (LABEL_1) - Confidence: 0.59
##oto (LABEL_0) - Confidence: 0.60
##xic efficacy of the (LABEL_1) - Confidence: 0.63
hi (LABEL_0) - Confidence: 0.50
##fn - Î³ preparations on the growth (LABEL_1) - Confidence: 0.59
and (LABEL_0) - Confidence: 0.51
development of tumor cells, a (LABEL_1) - Confidence: 0.58
b (LABEL_0) - Confidence: 0.51
##c cell line ( mcf - 7 ) was treated with both recombinant protein forms in a time - (LABEL_1) - Confidence: 0.59
and (LABEL_0) - Confidence: 0.51
dose - dependent way. the highest level of inhibiting cell proliferation was detected at a concentration of 32. (LABEL_1) - Confidence: 0.59
00 (LABEL_0) - Confidence: 0.51
##pg / ml hifn - Î³ after 72h incubation. anti (LABEL_1) - Confidence: 0.60
##can (LABEL_0) - Confidence: 0.51
##cer and antiviral functions of (LABEL_1) - Confidence: 0.60
if (LABEL_0) - Confidence: 0.51
##n - Î³ were confirmed via the expression analysis of hub genes cd74, cxcl10, il (LABEL_1) - Confidence: 0.59
##6 (LABEL_0) - Confidence: 0.54
, and stat1 using rt - pcr. furthermore, the (LABEL_1) - Confidence: 0.60
hi (LABEL_0) - Confidence: 0.52
##fn - Î³ preparations were significantly able (LABEL_1) - Confidence: 0.59
to (LABEL_0) - Confidence: 0.52
up - (LABEL_1) - Confidence: 0.53
regulate (LABEL_0) - Confidence: 0.62
the (LABEL_1) - Confidence: 0.63
expression (LABEL_0) - Confidence: 0.50
of pro (LABEL_1) - Confidence: 0.56
##apopto (LABEL_0) - Confidence: 0.52
##tic (LABEL_1) - Confidence: 0.59
bax (LABEL_0) - Confidence: 0.53
and p (LABEL_1) - Confidence: 0.54
##53 (LABEL_0) - Confidence: 0.52
and (LABEL_1) - Confidence: 0.51
to (LABEL_0) - Confidence: 0.50
down (LABEL_1) - Confidence: 0.52
- regulate (LABEL_0) - Confidence: 0.56
b (LABEL_1) - Confidence: 0.58
##cl - (LABEL_0) - Confidence: 0.60
2 as an antiapoptotic gene, showing the cyt (LABEL_1) - Confidence: 0.59
##oto (LABEL_0) - Confidence: 0.58
##xic effect of (LABEL_1) - Confidence: 0.63
hi (LABEL_0) - Confidence: 0.51
##fn - Î³ toward mcf - 7 cells via a (LABEL_1) - Confidence: 0.60
##poptosis (LABEL_0) - Confidence: 0.53
induction. copyright Â© 2025 elsevier b. v. all rights reserved. (LABEL_1) - Confidence: 0.63
doi (LABEL_0) - Confidence: 0.55
: (LABEL_1) - Confidence: 0.70
10 (LABEL_0) - Confidence: 0.60
. (LABEL_1) - Confidence: 0.57
101 (LABEL_0) - Confidence: 0.54
##6 / (LABEL_1) - Confidence: 0.56
j (LABEL_0) - Confidence: 0.54
. (LABEL_1) - Confidence: 0.54
j (LABEL_0) - Confidence: 0.52
##biotec. 2025. (LABEL_1) - Confidence: 0.54
04 (LABEL_0) - Confidence: 0.51
. 022 pmid : (LABEL_1) - Confidence: 0.60
40 (LABEL_0) - Confidence: 0.51
##348089 conflict o (LABEL_1) - Confidence: 0.67

----------------------------------------

--- SUMMARY for Chunk 35 ---
 The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper . f interest statement: Declaration of Competing Interest .

--- ENTITIES for Chunk 35 ---
f interest statement : declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper (LABEL_1) - Confidence: 0.66
. (LABEL_0) - Confidence: 0.58

----------------------------------------

